US20040058932A1 - Novel piperazine derivatives - Google Patents

Novel piperazine derivatives Download PDF

Info

Publication number
US20040058932A1
US20040058932A1 US10/660,052 US66005203A US2004058932A1 US 20040058932 A1 US20040058932 A1 US 20040058932A1 US 66005203 A US66005203 A US 66005203A US 2004058932 A1 US2004058932 A1 US 2004058932A1
Authority
US
United States
Prior art keywords
alkyl
alkylsulfonylamino
amino
alkylamino
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/660,052
Inventor
Laura Blumberg
Matthew Brown
Ronald Gladue
Molly McGlynn
Christopher Poss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Priority to US10/660,052 priority Critical patent/US20040058932A1/en
Publication of US20040058932A1 publication Critical patent/US20040058932A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/30—Nitrogen atoms non-acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D521/00—Heterocyclic compounds containing unspecified hetero rings

Definitions

  • the present invention relates to novel piperazine derivatives, methods of use and pharmaceutical compositions containing them.
  • the compounds of the invention are potent and selective inhibitors of chemokine binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes).
  • CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes).
  • the CCR1 receptor is also sometimes referred to as the CC-CKR1 receptor.
  • MIP-1 ⁇ and the related chemokines shown to interact with CCR1 (eq., RANTES and MCP-3)) induced chemotaxis of THP-1 cells and human leukocytes and are potentially useful for the treatment or prevention of autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), chronic bronchitis, xeno-transplantation, transplantation tissue
  • Compounds in this series may also limit the production of cytokines at inflammatory sites, including but not limited to TNF and IL-1, as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1, including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1, HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex).
  • cytokines at inflammatory sites including but not limited to TNF and IL-1, as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1, including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1, HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes
  • TNF inflammatory cytokines
  • TNF e.g, fungal meningitis, joint tissue damage, hyperplasia, pannus formation and bone resorption, psoriatic arthritis, hepatic failure, bacterial meningitis, Kawasaki syndrome, myocardial infarction, acute liver failure, lyme disease, septic shock, cancer, trauma, and malaria.
  • MIP-1 ⁇ and RANTES are soluble chemotactic peptides (chemokines) which are produced by inflammatory cells, in particular CD8+ lymphocytes, polymorphonuclear leukocytes (PMNs) and macrophages, J. Biol. Chem., 270 (30) 29671-29675 (1995). These chemokines act by inducing the migration and activation of key inflammatory and immunomodulatory cells. Elevated levels of chemokines have been found in the synovial fluid of rheumatoid arthritis patients, chronic and acute rejecting tissue from transplant patients and in the nasal secretions of allergic rhinitis patients following allergen exposure (Teran, et al., J.
  • the present invention also relates to a compound of the formula
  • a is 1, 2, 3, 4 or 5;
  • b is 0, 1, 2, 3 or 4;
  • c is 0 or 1;
  • d is 1,2, 3, 4 or 5;
  • e is 0 or 1;
  • j is 1, 2, 3, or 4;
  • X is C(O), C(S) or CH 2 ;
  • Y is CH 2 , or if e is 0, Y is CHR 8 wherein R 8 is hydrogen, (C 6 -C 10 )aryl or NR 9 R 10 ;
  • Z is oxygen, NR 9 or CR 11 R 12 ;
  • each R 1 is independently selected from hydrogen, hydroxy, hydroxysulfonyl, halo, (C 1 -C 6 )alkyl, mercapto, mercapto(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkylsulfinyl, (C 1 -C 6 )alkylsufonyl, (C 1 -C 6 )alkylthio(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylsulfinyl(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylsulfonyl(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 6 -C 10 )aryloxy, halo(C 1 -C 6 )alkyl, trifluoromethyl, for
  • each R 2 and R 3 are independently selected from oxo, halo, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 3 -C 8 )cycloalkyl(C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkylamino(C 1 -C 6 )alkyl, (C 3 -C 2 - 8 )cycloalkyl(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 6 -C 10 )aryl, (C 6 -C 10 )aryl(C 1 -C 6 )alkyl, (C 6 -C 10 )aryl(C 2 -C 6 )alkeny
  • R 4 is (R 5 ) f (R 6 ) g (C 6 -C 10 )aryl, (R 5 ) f (R 6 ) g (C 3 -C 10 )cycloalkyl, (R 5 ) f (R 7 ) h (C 2 -C 9 )heteroaryl, or (R 5 ) f (R 7 ) h (C 2 -C 9 )heterocycloalkyl,
  • f 1, 2, 3 or 4;
  • g and h are each independently 0, 1, 2 or 3;
  • R 5 is one to three groups independently selected from (C 2 -C 9 )heterocycloalkylcarbonyl, (C 2 -C 9 )heteroarylcarbonyl, (C 2 -C 9 )heteroaryl(C 1 -C 6 )alkylaminocarbonyl, (C 2 -C 9 )heterocycloalkyl(C 1 -C 6 )alkylaminocarbonyl, (C 1 -C 6 )alkylsulfonylamino(C 1 -C 6 )alkylaminocarbonyl, ureido(C 1 -C 6 )alkylaminocarbonyl, (C 1 -C 6 )alkylureido(C 1 -C 6 )alkylaminocarbonyl, ((C 1 -C 6 )alkyl) 2 ureido(C 1 -C 6 )alkylaminocarbonyl, hal
  • R 7 is one to three groups independently selected from hydrogen, hydroxy, halo, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkylsulfonyl, (C 6 -C 10 )arylsulfonyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkyl, fomyl, nitro, cyano, halo(C 1 -C 6 )alkoxy, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 6 -C 10 )aryl, (C 6 -C 10 )aryl(C 1 -C 6 )alkyl, amino, (C 1 -C 6 )alkylamino, ((C 1 -C 6 )alkyl) 2 amino, (C 6 -C 10 )arylamin
  • R 9 and R 10 are each independently selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl, (C 6 -C 10 )aryl, (C 6 -C 10 )aryl(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylcarbonyl, (C 1 -C 6 )alkylcarbonyl(C 1 -C 6 )alkyl, (C 6 -C 10 )aryl(C 1 -C 6 )alkylcarbonyl, (C 6 -C 10 )aryl(C 1 -C 6 )alkylcarbonyl(C 1 -C 6 )alkyl, aminocarbonyl, (C 1 -C 6 )alkylaminocarbonyl, ((C 1 -C 6 )alkyl) 2 aminocarbonyl and (C 1 -C 6 )alkoxycarbonyl; and R 11 and R 12 are each independently selected from the group consisting of
  • Preferred compounds of formula I include those wherein R 1 is hydrogen, halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C 1 -C 6 )alkyl, hydroxy or (C 1 -C 6 )alkylcarbonyloxy.
  • R 2 and R 3 are each independently selected from (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, amino(C 1 -C 6 )alkyl, amino(C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylamino(C 3 -C 8 )cycloalkyl, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxycarbonylamino(C 1 -C 6 )alkyl, ureido(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyureido(C 1 -C 6 )alkyl, (C 2 -C 9 )heteroaryl(C 1 -C 6 )alkyl
  • Other preferred compounds of formula I include those wherein c is 1; X is C(O); d is 1; Y is CHR 8 wherein R 8 is NR 9 R 10 ; R 9 and R 10 are each independently hydrogen, (C 1 -C 6 )alkyl or (C 1 -C 6 )alkylcarbonyl; e is 1; and Z is oxygen.
  • Other preferred compounds of formula I include those wherein c is 1; X is C(O); d is 1; Y is CHR 8 wherein R 8 is NR 9 R 10 ; R 9 and R 10 are each independently hydrogen, (C 1 -C 6 )alkyl or (C 1 -C 6 )alkylcarbonyl; e is 1; and Z is CR 11 R 12 wherein R 11 and R 12 are hydrogen.
  • Other preferred compounds of formula I include those wherein c is 1; X is C(O); d is 1; Y is CHR 8 wherein R 8 is NR 9 R 10 ; R 9 and R10 are each independently hydrogen, (C 1 -C 6 )alkyl or (C 1 -C 6 )alkylcarbonyl; e is 1; and Z is NR 9 wherein R 9 is hydrogen or (C 1 -C 6 )alkyl.
  • Other preferred compounds of formula I include those wherein c is 1; X is CH 2 ; d is 1; Y is CHR 8 wherein R 8 is NR 9 R 10 ; R 9 and R10 are each independently hydrogen, (C 1 -C 6 )alkyl or (C 1 -C 6 )alkylcarbonyl; e is 1; and Z is oxygen.
  • Other preferred compounds of formula I include those wherein c is 1; X is CH 2 ; d is 1; Y is CHR 8 wherein R 8 is NR 9 R 10 ; R 9 and R 10 are each independently hydrogen, (C 1 -C 6 )alkyl or (C 1 -C 6 )alkylcarbonyl; e is 1; and Z is CR 11 R 12 wherein R 11 and R 12 are hydrogen.
  • Other preferred compounds of formula I include those wherein c is 1; X is CH 2 ; d is 1; Y is CHR 8 wherein R 8 is NR 9 R 10 ; R 9 and R 10 are each independently hydrogen, (C 1 -C 6 )alkyl or (C 1 -C 6 )alkylcarbonyl; e is 1; and Z is NR 9 wherein R 9 is hydrogen or (C 1 -C 6 )alkyl.
  • R 4 is (R 5 ) f (R 6 ) g (C 6 -C 10 )aryl or (R 5 ) f (R 7 ) h (C 2 -C 9 )heteroaryl wherein f, g and h are independently 1 or 2.
  • R 5 is (C 2 -C 9 )heterocycloalkylcarbonyl, (C 2 -C 9 )heteroarylcarbonyl, (C 2 -C 9 )heteroaryl(C 1 -C 6 )alkylaminocarbonyl, (C 2 -C 9 )heterocycloalkyl(C 1 -C 6 )alkylaminocarbonyl, (C 1 -C 6 )alkylsulfonylamino(C 1 -C 6 )alkylaminocarbonyl, ureido(C 1 -C 6 )alkylaminocarbonyl, (C 1 -C 6 )alkylureido(C 1 -C 6 )alkylaminocarbonyl, ((C 1 -C 6 )alkyl) 2 ureido(C 1 -C 6 )alkylaminocarbonyl, ((C 1 -C 6 )alky
  • R 5 is (C 1 -C 6 )alkylsulfonylamino(C 1 -C 6 )alkylcarbonylamino, cyanoguanidino(C 1 -C 6 )alkylcarbonylamino, (C 1 -C 6 )alkylcyanoguanidino(C 1 -C 6 )alkylcarbonylamino, ((C, —C 6 )alkyl) 2 cyanoguanidino(C 1 -C 6 )alkylcarbonylamino, aminocarbonyl(C 1 -C 6 )alkylcarbonylamino, (C 2 -C 9 )heteroaryl(C 1 -C 6 )alkylcarbonylamino, (C 2 -C 9 )heterocycloalkyl(C 1 -C 6 )alkylcarbonylamino, or aminosulfonyl(C 1 -C 6 )alkylcarbonyla
  • R 5 is amino(C 1 -C 6 )alkylureido, (C 1 -C 6 )alkylamino(C 1 -C 6 )alkylureido, ((C 1 -C 6 )alkyl) 2 amino(C 1 -C 6 )alkylureido, (C 2 -C 9 )heterocycloalkyl(C 1 -C 6 )alkylureido, (C 2 -C 9 )heteroaryl(C 1 -C 6 )alkylureido, aminosulfonyl(C 1 -C 6 )alkylureido, aminocarbonyl(C 1 -C 6 )alkylureido, (C 1 -C 6 )alkylaminocarbonyl(C 1 -C 6 )alkylureido, ((C 1 -C 6 )alkylureido, ((C 1 -C
  • R 5 is amino(C 1 -C 6 )alkylsulfonylamino, (C 1 -C 6 )alkylamino(C 1 -C 6 )alkylsulfonylamino, ((C 1 -C 6 )alkyl) 2 amino(C 1 -C 6 )alkylsulfonylamino, acetylamino(C 1 -C 6 )alkylsulfonylamino, (acetyl)((C 1 -C 6 )alkyl)amino(C 1 -C 6 )alkylsulfonylamino, ureido(C 1 -C 6 )alkylsulfonylamino, (C 1 -C 6 )alkylureido(C 1 -C 6 )alkylsulfonylamino, ((C 1 -C 6 )alkylureido(C 1 -
  • R 5 is cyanoguanidino, (C 1 -C 6 )alkylcyanoguanidino, ((C 1 -C 6 )alkyl) 2 cyanoguanidino, (C 2 -C 9 )heterocycloalkylcyanoguanidino, (C 2 -C 9 )heteroarylcyanoguanidino, (C 2 -C 9 )heterocycloalkyl(C 1 -C 6 )alkylcyanoguanidino, (C 2 -C 9 )heteroaryl(C 1 -C 6 )alkylcyanoguanidino, amino(C 1 -C 6 )alkylcyanoguanidino, (C 1 -C 6 )alkylamino(C 1 -C 6 )alkylcyanoguanidino, ((C 1 -C 6 )alkyl) 2 amino(C 1 -
  • R 5 is aminocarbonyl(C 1 -C 6 )alkylamino, (C 1 -C 6 )alkylsulfonylamino(C 1 -C 6 )alkylamino, (C 1 -C 6 )alkoxycarbonylamino(C 1 -C 6 )alkylamino, aminosulfonyl(C 1 -C 6 )alkylamino, (C 2 -C 9 )heteroaryl(C 1 -C 6 )alkylamino, acetylamino(C 1 -C 6 )alkylamino or (acetyl)((C 1 -C 6 )alkyl)amino(C 1 -C 6 )alkylamino.
  • R 5 is cyano(C 1 -C 6 )alkylaminoalkyl or aminocarbonyl(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl.
  • R 5 is acetylamino(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl, (acetyl)((C 1 -C 6 )alkyl)amino(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxycarbonylamino(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl, (C 2 -C 9 )heterocycloalkyloxycarbonylamino(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl, (C 2 -C 9 )heteroaryloxycarbonylamino(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl, cyanoguanidino(C 1 -C 1 -C 6 )
  • R 5 is acetylamino(C 1 -C 6 )alkylcarbonylamino(C 1 -C 6 )alkyl, (acetyl)((C 1 -C 6 )alkyl)amino(C 1 -C 6 )alkylcarbonylamino(C 1 -C 6 )alkyl, aminocarbonyl(C 1 -C 6 )alkylcarbonylamino(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylaminocarbonyl(C 1 -C 6 )alkylcarbonylamino(C 1 -C 6 )alkyl, ((C 1 -C 6 )alkyl) 2 aminocarbonyl(C 1 -C 6 )alkylcarbonylamino(C 1 -C 6 )alkyl, aminosulfonyl(C 1 -C 6 )alkyl, aminosulfonyl(C 1
  • R 5 is amino(C 1 -C 6 )alkylaminocarbonylamino(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylamino(C 1 -C 6 )alkylaminocarbonyl amino(C 1 -C 6 )alkyl, ((C 1 -C 6 )alkyl) 2 amino(C 1 -C 6 )alkylaminocarbonylamino(C 1 -C 6 )alkyl, aminocarbonyl(C 1 -C 6 )alkylaminocarbonylamino(C 1 -C 6 )alkyl, (C 1 -C 6 ) alkylcarbonylamino(C 1 -C 6 )alkylaminocarbonylamino(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylsulfonylamino(C 1 -C 6
  • R 5 is amino(C 1 -C 6 )alkylsulfonylamino(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylamino(C 1 -C 6 )alkylsulfonylamino(C 1 -C 6 )alkyl, ((C 1 -C 6 )alkyl) 2 amino(C 1 -C 6 )alkylsulfonylamino(C 1 -C 6 )alkyl, acetylamino(C 1 -C 6 )alkylsulfonylamino(C 1 -C 6 )alkyl, (acetyl)((C 1 -C 6 )alkyl)amino(C 1 -C 6 )alkylsulfonylamino(C 1 -C 6 )alkyl, ureido(C 1 -C 6 )alkyl,
  • R 5 is cyanoguanidino(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl(cyanoguanidino)(C 1 -C 6 )alkyl, ((C 1 -C 6 )alkyl) 2 (cyanoguanidino)(C 1 -C 6 )alkyl, (C 2 -C 9 )heterocycloalkyl(cyanoguanidino)(C 1 -C 6 )alkyl, (C 2 -C 9 )heteroaryl(cyanoguanidino)(C 1 -C 6 )alkyl, (C 2 -C 9 )heterocycloalkyl(C 1 -C 6 )alkyl(cyanoguanidino)(C 1 -C 6 )alkyl, (C 2 -C 9 )heteroaryl(C 1 -C 6 )alkyl, (C 2 -C 9 )hetero
  • R 5 is (C 2 -C 9 )heterocycloalkylsulfonyl, amino(C 1 -C 6 )alkylaminosulfonyl, (C 1 -C 6 )alkylamino(C 1 -C 6 )alkylaminosulfonyl, ((C 1 -C 6 )alkyl) 2 amino(C 1 -C 6 )alkylaminosulfonyl, (C 2 -C 9 )heteroarylaminosulfonyl, ureido(C 1 -C 6 )alkylaminosulfonyl, (C 1 -C 6 )alkylureido(C 1 -C 6 )alkylaminosulfonyl, ((C 1 -C 6 )alkyl) 2 ureido(C 1 -C 6 )alkylaminosulfonyl,
  • R 6 and R 7 are each independently halo, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, trifluoromethyl, trifluoromethoxy, hydroxy, aminocarbonyl, cyano, ureido, (C 1 -C 6 )alkylsulfonylamino, (C 1 -C 6 )alkoxycarbonylamino or glycinamino.
  • the present invention also relates to the pharmaceutically acceptable acid addition salts of compounds of the formula I.
  • the acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [, 1,1′-methylene-bis-(2-hydroxy-3-naphthoate)]salts.
  • the invention also relates to base addition salts of formula I.
  • the chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of formula I that are acidic in nature are those that form non-toxic base salts with such compounds.
  • Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (ea., potassium and sodium) and alkaline earth metal cations (eq., calcium and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.
  • the compounds of this invention may contain olefin-like double bonds. When such bonds are present, the compounds of the invention exist as cis and trans configurations and as mixtures thereof.
  • the present invention also relates to compounds of formula I wherein any of the hydrogens may optionally be replaced by deuterium.
  • alkyl, alkenyl and alkynyl groups referred to herein, as well as the alkyl moieties of other groups referred to herein (e.g., alkoxy), may be linear or branched, and they may also be cyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl) or be linear or branched and contain cyclic moieties.
  • halogen includes fluorine, chlorine, bromine, and iodine.
  • (C 3 -C 10 )Cycloalkyl when used herein refers to cycloalkyl groups containing zero to two levels of unsaturation such as cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, 1,3-cyclohexadiene, cycloheptyl, cycloheptenyl, bicyclo[3.2.1]octane, norbornanyl etc.
  • (C 2 -C 9 )Heterocycloalkyl when used herein refers to pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyranyl, pyranyl, thiopyranyl, aziridinyl, oxiranyl, methylenedioxyl, chromenyl, barbituryl, isoxazolidinyl, 1,3-oxazolidin-3-yl, isothiazolidinyl, 1,3-thiazolidin-3-yl, 1,2-pyrazolidin-2-yl, 1,3-pyrazolidin-1-yl, piperidinyl, thiomorpholinyl, 1,2-tetrahydrothiazin-2-yl, 1,3-tetrahydrothiazin-3-yl, tetrahydrothiadiazinyl, morpholinyl, 1,2-tetrahydrodiazin-2-yl, 1,3-tetrahydrodiazin
  • (C 2 -C 9 )Heteroaryl when used herein refers to furyl, thienyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, 1,3,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-oxadiazolyl, 1,3,5-thiadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, 1,3,5-triazinyl, pyrazolo[3,4-b]pyridinyl, cinnolinyl, pteridinyl, purinyl, 6,7
  • Aryl when used herein refers to phenyl or naphthyl.
  • ureido refers to an “amino-carbonyl-amino” moiety.
  • acetyl refers to an “alkyl-carbonyl” moiety wherein alkyl is defined as above.
  • cyanoguanidino refers to a functional group having the following formula
  • (C 2 -C 9 )heterocycloalkyl(C ⁇ N—CN)amino refers to a functional group having the following formula
  • HET refers to a (C 2 -C 9 )heterocyloalkyl or (C 2 -C 9 )heteroaryl group and the nigrogen of said group is the place of attachment.
  • mercapto refers to a “HS-” moeity.
  • the compounds of this invention include all conformational isomers (e.g., cis and trans isomers) and all optical isomers of compounds of the formula I (e.g., enantiomers and diastereomers), as well as racemic, diastereomeric and other mixtures of such isomers.
  • the present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases, rheumatoid arthritis, recent onset type I diabetes, lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, vasculitis, acute and chronic inflammatory conditions, osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, glomerulonephritis, allergic conditions, asthma, atopic dermatitis, infection associated with inflammation, viral inflammation, influenza, hepatitis, Guillian-Barre, chronic bronchitis, xeno-transplantation, chronic and acute transplantation tissue rejection, chronic and acute organ transplant rejection, atherosclerosis, restenosis, HIV infectivity, granulomatous diseases, sarcoidosis, leprosy and tuberculosis and
  • Compounds in this series may also limit the production of cytokines at inflammatory sites, including but not limited to TNF and IL-1, as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1, including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1, HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex).
  • cytokines at inflammatory sites including but not limited to TNF and IL-1, as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1, including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1, HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes
  • TNF inflammatory cytokines
  • mammal preferably a human
  • an amount of a compound of the formula I or a pharmaceutically acceptable salt thereof effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier comprising an amount of a compound of the formula I or a pharmaceutically acceptable salt thereof effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.
  • the present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by inhibiting chemokine binding to the receptor CCR1 in a mammal, preferably a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by inhibiting chemokine binding to the receptor CCR1 in a mammal, preferably a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.
  • disorders and conditions are those enumerated in the preceding paragraph.
  • the present invention also relates to a method for treating or preventing a disorder or condition selected from autoimmune diseases, rheumatoid arthritis, recent onset type I diabetes, lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, vasculitis, acute and chronic inflammatory conditions, osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, glomerulonephritis, allergic conditions, asthma, atopic dermatitis, infection associated with inflammation, viral inflammation, influenza, hepatitis, Guillian-Barre, chronic bronchitis, xeno-transplantation, chronic and acute transplantation tissue rejection, chronic and acute organ transplant rejection, atherosclerosis, restenosis, HIV infectivity, granulomatous diseases, sarcoidosis, leprosy and tuberculosis and sequel
  • Compounds in this series may also limit the production of cytokines at inflammatory sites, including but not limited to TNF and IL-1, as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1, including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1, HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex).
  • cytokines at inflammatory sites including but not limited to TNF and IL-1, as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1, including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1, HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes
  • TNF inflammatory cytokines
  • mammal preferably a human
  • administering to a mammal in need of such treatment or prevention an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.
  • the present invention also relates to a method for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.
  • the present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases, rheumatoid arthritis, recent onset type I diabetes, lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, vasculitis, acute and chronic inflammatory conditions, osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, glomerulonephritis, allergic conditions, asthma, atopic dermatitis, infection associated with inflammation, viral inflammation, influenza, hepatitis, Guillian-Barre, chronic bronchitis, xeno-transplantation, chronic and acute transplantation tissue rejection, chronic and acute organ transplant rejection, atherosclerosis, restenosis, HIV infectivity, granulomatous diseases, sarcoidosis, leprosy and tuberculosis and
  • Compounds in this series may also limit the production of cytokines at inflammatory sites, including but not limited to TNF and IL-1, as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1, including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1, HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex).
  • cytokines at inflammatory sites including but not limited to TNF and IL-1, as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1, including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1, HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes
  • TNF inflammatory cytokines
  • mammal preferably a human, comprising a CCR1 receptor antagonizing effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • the present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, preferably a human, comprising a CCR1 receptor antagonizing effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • the present invention also relates to a method for treating or preventing a disorder or condition selected from autoimmune diseases, rheumatoid arthritis, recent onset type I diabetes, lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, vasculitis, acute and chronic inflammatory conditions, osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, glomerulonephritis, allergic conditions, asthma, atopic dermatitis, infection associated with inflammation, viral inflammation, influenza, hepatitis, Guillian-Barre, chronic bronchitis, xeno-transplantation, chronic and acute transplantation tissue rejection, chronic and acute organ transplant rejection, atherosclerosis, restenosis, HIV infectivity, granulomatous diseases, sarcoidosis, leprosy and tuberculosis and sequel
  • Compounds in this series may also limit the production of cytokines at inflammatory sites, including but not limited to TNF and IL-1, as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1, including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1, HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex).
  • cytokines at inflammatory sites including but not limited to TNF and IL-1, as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1, including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1, HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes
  • TNF inflammatory cytokines
  • cytokines such as TNF e.g, fungal meningitis, joint tissue damage, hyperplasia, pannus formation and bone resorption, psoriatic arthritis, hepatic failure, bacterial meningitis, Kawasaki syndrome, myocardial infarction, acute liver failure, lyme disease, septic shock, cancer, trauma, and malaria in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention a CCR1 receptor antagonizing effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof.
  • TNF e.g, fungal meningitis, joint tissue damage, hyperplasia, pannus formation and bone resorption, psoriatic arthritis, hepatic failure, bacterial meningitis, Kawasaki syndrome, myocardial infarction, acute liver failure, lyme disease, septic shock, cancer, trauma, and malaria in a mam
  • R 16 and R 17 together with the nitrogen to which they are attached is selected from the group consisting of amino, amino(C 1 -C 6 )alkylcarbonylamino, (C 1 -C 6 )alkylamino(C 1 -C 6 )alkylcarbonylamino, ((C 1 -C 6 )alkyl) 2 amino(C 1 -C 6 )alkylcarbonylamino, acetylamino(C 1 -C 6 )alkylcarbonylamino, (acetyl)((C 1 -C 6 )alkyl)amino(C 1 -C 6 )alkylcarbonylamino, (C 1 -C 6 )alkylsulfonylamino(C 1 -C 6 )alkylcarbonylamino, cyanoguanidino(C 1 -C 6 )alkylcarbonylamino, (C 1 -C 6 )alkylcyan
  • R 18 and R 19 together with the nitrogen to which they are attached is selected from the group consisting of (C 2 -C 9 )heteroaryl(C 1 -C 6 )alkylamino, (C 2 -C 9 )heterocycloalkyl(C 1 -C 6 )alkylamino, (C 1 -C 6 )alkylsulfonylamino, (C 1 -C 6 )alkylsulfonylamino(C 1 -C 6 )alkylamino, ureido(C 1 -C 6 )alkylamino, (C 1 -C 6 )alkylureido(C 1 -C 6 )alkylamino, ((C 1 -C 6 )alkyl) 2 ureido(C 1 -C 6 )alkylamino, halo(C 1 -C 6 )alkylamino, aminosulfonyl(
  • reaction 2 of Preparation A the compound of formula XXXIV is converted to the corresponding compound of formula XXXIII by reducing XXXIV with a reducing agent, such as sodium borohydride, in a refluxing protic solvent, such as ethanol.
  • a reducing agent such as sodium borohydride
  • a refluxing protic solvent such as ethanol
  • reaction 3 of Preparation A the compound of formula XXXIII is converted to the corresponding compound of formula XXX by reacting XXXIII with a benzaldehyde compound of the formula
  • reaction mixture in the presence of a base, such as triethylamine, and a reducing agent, such as sodium triacetoxyborohydride, in an aprotic solvent, such as 1,2-dichloroethane.
  • a base such as triethylamine
  • a reducing agent such as sodium triacetoxyborohydride
  • an aprotic solvent such as 1,2-dichloroethane
  • reaction 1 of Preparation B the compound of formula XXII, wherein b is 0, 1 or 2, is converted to the corresponding compound of formula XXI by reacting XXIII with a benzaldehyde compound of the formula
  • a base such as triethylamine
  • a reducing agent such as sodium borohydride
  • an aprotic solvent such as 1,2-dichloroethane
  • reaction 2 of Preparation B the compound of formula XXI is converted to the corresponding compound of formula XX by first reacting a compound of the formula
  • reaction 3 of Preparation B the compound of formula XX is converted to the corresponding piperizine-2,5-dione compound of formula XIX by treating XX with trifluoroacetic acid in the presence of a polar aprotic solvent, such as methylene chloride.
  • a polar aprotic solvent such as methylene chloride.
  • reaction 4 of Preparation B the compound of formula XIX is converted to the corresponding compound of formula XVIII by reducing XIX with a reducing agent, such as lithium aluminum hydride.
  • a reducing agent such as lithium aluminum hydride.
  • the reaction is conducted at a temperature between about ⁇ 10C to about 10C, preferably about 0° C., for a time period between about 10 minutes to about 90 minutes, preferably about 40 minutes.
  • reaction 1 of the Preparation C the compound of formula XXV is converted to the corresponding compound of formula XXIV by reacting XXV with an amine of the formula, NHR 18 R 19 , wherein R 18 and R 19 are each independently selected from hydrogen, a nitrogen containing (C 2 -C 9 )heterocycloalkyl or (C 2 -C 9 )heteroaryl group, or (C 1 -C 6 )alkyl optionally substituted by hydroxy, aminocarbonyl, (C 1 -C 6 )alkylaminocarbonyl, ((C 1 -C 6 )alkyl) 2 carbonyl, carboxy, (C 1 -C 6 )alkylsulfonylamino, (C 1 -C 6 )alkoxycarbonylamino, aminosulfonyl, (C 1 -C 6 )alkylaminosulfonyl, ((C 1 -C 6 )alky
  • reaction 2 of Preparation C the compound of formula XXIV is converted to the corresponding compound of formula XXIII by reacting XXIV with thiophenol in the presence of a base, such as sodium hydride, and a polar aprotic solvent, such as dimethylformamide.
  • a base such as sodium hydride
  • a polar aprotic solvent such as dimethylformamide
  • reaction 3 of Preparation C the compound of formula XXV is converted to the corresponding compound of formula XXXVIII by reacting XXV with sodium cyanate in the presence of pyridine and a polar aprotic solvent, such as acetonitrile.
  • the reaction is stirred, at room temperature, for a time period between about 2 hours to about 18 hours, preferably about 10 hours.
  • An amine of the formula, H 2 N—C(O)—NR 18 R 19 is then added and the reaction mixture so formed is stirred, at room temperature, for a time period between about 2 hours to about 24 hours, preferably about 8 hours.
  • reaction 4 of Preparation C the compound of formula XXXVIII is converted to the corresponding compound of formula XXXVII according to the procedure described above in reaction 2 of Preparation C.
  • reaction 1 of Scheme 1 the compound of formula XXX is converted to the corresponding compound of formula X by reacting XXX with a compound of the formula, A-(X) c —(Y) d -A, wherein A is chloro or bromo, in the presence of a base, such as triethylamine, and a polar aprotic solvent, such as methylene chloride.
  • a base such as triethylamine
  • a polar aprotic solvent such as methylene chloride
  • reaction 2 of Scheme 1 the compound of formula X is converted to the corresponding compound of formula I by reacting X with a compound of the formula, H-(Z) e -R 4 wherein e is 1 and Z is oxygen, in the presence of potassium carbonate, potassium iodide and an aprotic solvent, such as butanone.
  • the reaction is heated to reflux for a time period between about 4 hours to about 8 hours, preferably about 6 hours.
  • reaction 1 of Scheme 2 the compound of formula XXX is converted to the corresponding compound of formula I by reacting XXX with a compound of the formula, A-(X) c —(Y) d -(Z) e -R 4 , wherein A is chloro or bromo, in the presence of a base, such as triethylamine, and a polar aprotic solvent, such as methylene chloride.
  • a base such as triethylamine
  • a polar aprotic solvent such as methylene chloride
  • reaction 1 of Scheme 3 the compound of formula X is converted to the corresponding compound of formula XII according to the procedure described above in reaction 2 of Scheme 1.
  • reaction 2 of Scheme 3 the compound of formula XII is converted to the corresponding compound of formula XI by reacting XlI with lithium hydroxide monohydrate in the presence of methanol, tetrahydrofuran and water. The reaction mixture is stirred overnight at room temperature.
  • reaction 3 of Scheme 4 for urea formation, the compound of formula XIV is converted to the corresponding compound of formula V by first reacting XIV with 4-nitrophenyl chloroformate in the presence of a base, such as pyridine, and a polar aprotic solvent, such as methlyene chloride, followed by reacting the intermediate so formed with an amine.
  • a base such as pyridine
  • a polar aprotic solvent such as methlyene chloride
  • the compound of formula XIV is reacted with a sulfonyl chloride compound of the formula, R 16 —Cl, in the presence of a base, such as triethylamine, and a polar aprotic solvent, such as methylene chloride. The reaction is stirred overnight at ambient temperature.
  • a base such as triethylamine
  • a polar aprotic solvent such as methylene chloride.
  • cyanoguanidine formation the compound of formula XIV is first treated with sodium hydride in an aprotic solvent, such as tetrahydrofuran, followed by reacting, the intermediate so formed with dimethyl-N-cyanodithio iminocarbonate. The reaction mixture so formed is heated to reflux overnight.
  • N-cyano-S-methyl-isothiourea intermediate is then reacted with an amine in the presence of a polar protic solvent, such as methanol.
  • a polar protic solvent such as methanol.
  • the compound of formula XIV is reacted with an acid, such as 3-tert-butoxycarbonylaminopropionic acid in the presence of N-methylmorpholine, O-benzotriazole-1-yl-N,N,N, N-tetramethyluronium hexafluorophosphate and a polar aprotic solvent, such as methylene chloride.
  • reaction 1 of Scheme 5 the compound of formula X is converted to the corresponding compound of formula XVI, wherein k is 0, 1, 2, 3 or 4, according to the procedure described above in reaction 2 of Scheme 1.
  • reaction 2 of Scheme 5 the compound of formula XVI is converted to the corresponding compound of formula VII by reacting XVI with an amine of the formula, R 16 R 17 N, wherein R 16 and R 17 are each indepenently hydrogen, a nitrogen containing (C 2 -C 9 )heterocycloalkyl or (C 2 -C 9 )heteroaryl group, or (C 1 -C 6 )alkyl optionally substituted by hydroxy, aminocarbonyl, (C 1 -C 6 )alkylaminocarbonyl, ((C 1 -C 6 )alkyl) 2 carbonyl, carboxy, (C 1 -C 6 )alkylsulfonylamino, (C 1 -C 6 )alkoxycarbonylamino, aminosulfonyl, (C 1 -C 6 )alkylaminosulfonyl,
  • reaction 1 of Scheme 6 the compound of formula X is converted to the corresponding compound of formula XXXIX according to the procedure described above in reaction 2 of Scheme 1.
  • reaction 2 of Scheme 6 the compound of formua X is converted to the corresponding compound of formula XXXX according to the procedure described above in reaction 2 of Scheme 1.
  • reaction 1 of Scheme 7 the acid compound of formula XXXVI is converted to the corresponding compound of formula XXXII by treating XXXVI with thionyl chloride neat or in an aprotic solvent, at room temperature, for a time period between about 1 hour to about 24 hours, preferably 1 hour.
  • the acid chloride so formed is dissolved in a polar aprotic solvent with a compound of the formula, (H 3 CO)(H 3 C)NH.HCl, in the presence of an amine base, such as triethylamine.
  • the reaction mixture is stirred, at room temperature, for a time period between about 1 hour to about 48 hours, preferably about 12 hours.
  • the pressure of each of the above reactions is not critical. Generally, the reactions will be conducted at a pressure of about one to about three atmospheres, preferably at ambient pressure (about one atmosphere).
  • the compounds of the formula I which are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically acceptable acid addition salt.
  • the acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is obtained.
  • the acids which are used to prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [1,1′-methylene-bis-(2-hydroxy-3-naphthoate)] salts.
  • non-toxic acid addition salts i.e., salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate
  • salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure.
  • they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before.
  • stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum product yields.
  • the active compounds are potent antagonists of the CCR1 receptors.
  • the active compounds are useful in the treatment or prevention of autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult respiratory distress syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), chronic bronchitis, xeno-transplantation, transplantation tissue rejection, atherosclerosis, restenosis, HIV in
  • the activity of the compounds of the invention can be assessed according to procedures know to those of ordinary skill in the art. Examples of recognized methods for determining CCR1 induced migration can be found in Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M., Strober, W. editors: Current Protocols In Immunology, 6.12.1-6.12.3. (John Wiley and Sons, NY, 1991). One specific example of how to determine the activity of a compound for inhibiting migration is described in detail below.
  • the chamber is removed, the cells in the upper chamber aspirated, the upper part of the filter wiped and the number of cells migrating can be determined according to the following method.
  • the chamber (a 96 well variety manufactured by Neuroprobe) can be centrifuged to push cells off the lower chamber and the number of cells can be quantitated against a standard curve by a color change of the dye fluorocein diacetate.
  • the filter can be stained with Dif Quik® dye (American Scientific Products) and the number of cells migrating can be determined microscopically.
  • compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers.
  • the active compounds of the invention may be formulated for oral, buccal, intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or in a form suitable for administration by inhalation or insufflation.
  • the active compounds of the invention may also be formulated for sustained delivery.
  • the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate).
  • binding agents e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g., lactose, microcrystalline cellulose or calcium phosphate
  • lubricants e.g., magnesium stearate, talc or silica
  • disintegrants e.g., potato starch or sodium
  • composition may take the form of tablets or lozenges formulated in conventional manner.
  • the active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • the active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
  • the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • the pressurized container or nebulizer may contain a solution or suspension of the active compound.
  • Capsules and cartridges for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
  • a proposed dose of the active compounds of the invention for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above is 0.1 to 1000 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.
  • Aerosol formulations for treatment of the conditions referred to above (eq., rheumatoid arthritis) in the average adult human are preferably arranged so that each metered dose or “puff” of aerosol contains 20 ⁇ g to 1000 ⁇ g of the compound of the invention.
  • the overall daily dose with an aerosol will be within the range 0.1 mg to 1000 mg.
  • Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each time.
  • the active agents can be formulated for sustained delivery according to methods well known to those of ordinary skill in the art. Examples of such formulations can be found in U.S. Pat. Nos. 3,538,214, 4,060,598, 4,173,626, 3,119,742, and 3,492,397.
  • the compounds of the invention can also be utilized in combination therapy with, but not limited to, other therapeutic agents such as with T-cell immunosuppressant agents such as rapamycin cyclosporin A and FK-506, with steroid sparing agents such as Cellcept®, or with classical anti-inflammatory agents (e.g. cyclooxygenase/lipoxygenase inhibitors) such as tenidap, aspirin, acetaminophen, naproxen and piroxicam.
  • T-cell immunosuppressant agents such as rapamycin cyclosporin A and FK-506, with steroid sparing agents such as Cellcept®, or with classical anti-inflammatory agents (e.g. cyclooxygenase/lipoxygenase inhibitors) such as tenidap, aspirin, acetaminophen, naproxen and piroxicam.
  • T-cell immunosuppressant agents such as rapamycin cyclosporin A and FK-506, with
  • Example R 20 R 2 2 Me 3 Me 4 H 5 H 6 H 7 H 8 H 9 H 10 —NHSO 2 Me Me 11 —NH—(CH 2 ) 2 —NHSO 2 CH 3 CH 3 12 —NH—(CH 2 ) 2 —NHC(O)NH 2 CH 3
  • Example 21-27 The title compounds for Examples 21-27 were prepared by a method analogous to that described in Example 20.
  • Example R 20 R 2 21 Me 22 H 23 Me 24 H 25 H 26 H 27 Me
  • Example 29-34 The title compounds for Examples 29-34 were prepared by a method analogous to that described in Example 28.
  • Example R 20 R 2 40 Me 41 Me 42 Me 43 Me 44 Me 45 Me 46 Me 47 Me 48 Me 49 Me 50 Me 51 Me 52 Me 53 Me 54 Me 55 Me 56 Me 57 Me 58 Me 59 Me 60 Me 61 Me 62 Me
  • Example R 20 64 Me 65 Me 66 Me 67 Me 68 Me 69 Me 70 Me 71 Me 72 Me 73 Me 74 Me 75 Me 76 Me 77 Me 78 H 79 H 80 Me 81 Me 82 Me 83 Me 84 H 85 H
  • N-Acetylethylenediamine (0.019 mL, 0.188 mmol) was added and the reaction was stirred at room temperature over night. The reaction was concentrated in vacuo and chromatography on silica gel gave the title compound (0.019 g, 27%).
  • Example 87-90 The title compounds for Examples 87-90 were prepared by a method analogous to that described in Example 86.
  • Example 92-93 The title compounds for Examples 92-93 were prepared by a method analogous to that described in Example 91.
  • Example 95-96 were prepared by a method analogous to that described in Example 94.
  • Example 98-100 The title compounds for Examples 98-100 were prepared by a method analogous to that described in Example 97.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)

Abstract

A compound of the formula
Figure US20040058932A1-20040325-C00001
or the pharmaceutically acceptable salt thereof; wherein a, b, c, d, e, j, R1, R2, R3, and R4 are as defined above useful to treat inflammation and other immune disorders.

Description

  • This application claims the benefit of priority of provisional Patent Application Serial No. 60/193,789 filed Mar. 31, 2000, and nonprovisional patent application Ser. No. 09/821,322 filed Mar. 29, 2001, which is incorporated herein by reference in their entirety for all purposes.[0001]
    • BACKGROUND OF THE INVENTION
  • The present invention relates to novel piperazine derivatives, methods of use and pharmaceutical compositions containing them. [0002]
  • The compounds of the invention are potent and selective inhibitors of chemokine binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes). The CCR1 receptor is also sometimes referred to as the CC-CKR1 receptor. These compounds also inhibit MIP-1α (and the related chemokines shown to interact with CCR1 (eq., RANTES and MCP-3)) induced chemotaxis of THP-1 cells and human leukocytes and are potentially useful for the treatment or prevention of autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), chronic bronchitis, xeno-transplantation, transplantation tissue rejection (chronic and acute), organ transplant rejection (chronic and acute), atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases (including sarcoidosis, leprosy and tuberculosis) and sequelae associated with certain cancers such as multiple myeloma. Compounds in this series may also limit the production of cytokines at inflammatory sites, including but not limited to TNF and IL-1, as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1, including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1, HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex). They may also provide benefit for the sequelae associated with infection where such infection induces production of detrimental inflammatory cytokines such as TNF e.g, fungal meningitis, joint tissue damage, hyperplasia, pannus formation and bone resorption, psoriatic arthritis, hepatic failure, bacterial meningitis, Kawasaki syndrome, myocardial infarction, acute liver failure, lyme disease, septic shock, cancer, trauma, and malaria. [0003]
  • MIP-1α and RANTES are soluble chemotactic peptides (chemokines) which are produced by inflammatory cells, in particular CD8+ lymphocytes, polymorphonuclear leukocytes (PMNs) and macrophages, [0004] J. Biol. Chem., 270 (30) 29671-29675 (1995). These chemokines act by inducing the migration and activation of key inflammatory and immunomodulatory cells. Elevated levels of chemokines have been found in the synovial fluid of rheumatoid arthritis patients, chronic and acute rejecting tissue from transplant patients and in the nasal secretions of allergic rhinitis patients following allergen exposure (Teran, et al., J. Immunol., 1806-1812 (1996), and Kuna et al., J. Allergy Clin. Immunol. 321 (1994)). Antibodies which interfere with the chemokine/receptor interaction by neutralizing MIP1α or gene disruption have provided direct evidence for the role of MIP-1α and RANTES in disease by limiting the recruitment of monocytes and CD8+ lymphocytes (Smith et al., J. Immunol, 153, 4704 (1994) and Cook et al., Science, 269, 1583 (1995)). Together this data demonstrates that CCR1 receptor antagonists would be an effective treatment of several immune based diseases. The compounds described within are potent and selective antagonists of the CCR1 receptor.
    • SUMMARY OF THE INVENTION
  • The present invention also relates to a compound of the formula [0005]
    Figure US20040058932A1-20040325-C00002
  • or the pharmaceutically acceptable salt thereof; wherein [0006]
  • a is 1, 2, 3, 4 or 5; [0007]
  • b is 0, 1, 2, 3 or 4; [0008]
  • c is 0 or 1; [0009]
  • d is 1,2, 3, 4 or 5; [0010]
  • e is 0 or 1; [0011]
  • j is 1, 2, 3, or 4; [0012]
  • X is C(O), C(S) or CH[0013] 2;
  • Y is CH[0014] 2, or if e is 0, Y is CHR8 wherein R8 is hydrogen, (C6-C10)aryl or NR9R10;
  • Z is oxygen, NR[0015] 9 or CR11R12;
  • each R[0016] 1 is independently selected from hydrogen, hydroxy, hydroxysulfonyl, halo, (C1-C6)alkyl, mercapto, mercapto(C1-C6)alkyl, (C1-C6)alkylthio, (C1-C6)alkylsulfinyl, (C1-C6)alkylsufonyl, (C1-C6)alkylthio(C1-C6)alkyl, (C1-C6)alkylsulfinyl(C1-C6)alkyl, (C1-C6)alkylsulfonyl(C1-C6)alkyl, (C1-C6)alkoxy, (C6-C10)aryloxy, halo(C1-C6)alkyl, trifluoromethyl, formyl, formyl(C1-C6)alkyl, nitro, nitroso, cyano, (C6-C10)aryl(C1-C6)alkoxy, halo(C1-C6)alkoxy, trifluoromethoxy, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, hydroxy(C3-C7)cycloalkyl(C1-C6)alkyl, (C3-C7)cycloalkylamino, (C3-C7)cycloalkylamino(C1-C6)alkyl, ((C3-C7)cycloalkyl)((C1-C6)alkyl)amino, ((C3-C7)cycloalkyl(C1-C6)alkyl)amino(C1-C6)alkyl, cyano(C1-C6)alkyl, (C2-C7)alkenyl, (C2-C7)alkynyl, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl, (C6-C10)aryl(C2-C6)alkenyl, hydroxy(C1-C6)alkyl, hydroxy(C6-C10)aryl(C1-C6)alkyl, hydroxy(C1-C6)alkylthio(C1-C6)alkyl, hydroxy(C2-C6)alkenyl, hydroxy(C2-C6)alkynyl, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxy(C6-C10)aryl(C1-C6)alkyl, (C6-C10)aryloxy(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkoxy(C1-C6)alkyl, amino, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, (C6-C10)arylamino, (C6-C10)aryl(C1-C6)alkylamino, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkyl, hydroxy(C1-C6)alkylamino(C1-C6)alkyl, (C6-C10)arylamino(C1-C6)alkyl, (C6-C10)aryl (C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkylcarbonylamino, ((C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino, (C1-C6)alkylcarbonylamino(C1-C6)alkyl, ((C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino, (C1-C6)alkoxycarbonyl)(C1-C6)alkylamino, (C1-C6)alkoxycarbonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbnony)((C1-C6)alkyl)amino(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C6-C10)aryl(C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C1-C6)alkylcarbonyl(C1-C6)alkyl, (C6-C10)arylcarbonyl, (C6-C10)arylcarbonyl(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylcarbonyl, (C6-C10)aryl(C1-C6)alkycarbonyl(C1-C6)alkyl, carboxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkoxycarbonyl(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkylcarbonyloxy(C1-C6)alkyl, aminocarbonyl, (C1-C6)alkylaminocarbonyl, ((C1-C6)alkyl)2aminocarbonyl, (C6-C10)arylaminocarbonyl, (C6-C10)aryl(C1-C6)alkylaminocarbonyl, aminocarbonyl(C1-C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkyl, (C6-C10)arylaminocarbonyl(C1-C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkyl, amidino, guanidino, ureido, (C1-C6)alkylureido, ((C1-C6)alkyl)2ureido, ureido(C1-C6)alkyl, (C1-C6)alkylureido(C1-C6)alkyl, ((C1-C6)alkyl)2ureido(C1-C6)alkyl, (C2-C9)heterocycloalkyl, (C2-C9)heteroaryl, (C2-C9)heterocycloalkyl(C1-C6)alkyl and (C2-C9)heteroaryl(C1-C6)alkyl;
  • each R[0017] 2 and R3 are independently selected from oxo, halo, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C6)alkyl, (C3-C8)cycloalkylamino(C1-C6)alkyl, (C3-C2-8)cycloalkyl(C1-C6)alkylamino(C1-C6)alkyl, halo(C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl, (C6-C10)aryl(C2-C6)alkenyl, H—C(O)—, H—C(O)—(C1-C6)alkyl, hydroxy(C1-C6)alkyl, hydroxy(C2-C6)alkenyl, hydroxy(C2-C6)alkynyl, hydroxy(C6-C10)aryl(C1-C6)alkyl, hydroxy(C3-C8)cycloalkyl(C1-C6)alkyl, thio(C1-C6)alkyl, cyano(C1-C6)alkyl, halo(C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C1-C6)alkoxy(C6-C10)aryl(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, (C6-C10)aryloxy(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkylthio(C1-C6)alkyl, (C1-C6)alkylsulfinyl(C1-C6)alkyl, (C1-C6)alkylsulfonyl(C1-C6)alkyl, hydroxy(C1-C6)alkylthio(C1-C6)alkyl, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkyl, (C6-C10)arylamino(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkylcarbonylamino(C1-C6)alkyl, azido(C1-C6)alkyl, aminocarbonylamino(C1-C6)alkyl, (C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonyl(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkyl, hydroxy(C1-C6)alkylamino(C1-C6)alkyl, (C6-C10)aryloxy(C1-C6)alkylcarbonyloxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkylcarbonyloxy(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkoxy(C1-C6)alkylcarbonyloxy(C1-C6)alkyl, (C1-C6)alkylcarbonyl, (C1-C6)alkylcarbonyl(C1-C6)alkyl, carboxy, (C1-C6)alkoxycarbonyl, (C6-C10)aryl(C1-C6)alkoxycarbonyl, (C6-C10)aryl(C1-C6)alkylcarbonyl, aminocarbonyl, (C1-C6)alkylaminocarbonyl, ((C1-C6)alkyl)2aminocarbonyl, (C6-C10)arylaminocarbonyl, (C6-C10)aryl(C1-C6)alkylaminocarbonyl, carboxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkoxycarbonyl(C1-C6)alkyl, aminocarbonyl(C1-C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkyl, (C6-C10)arylaminocarbonyl(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylaminocarbonyl(C1-C6)alkyl, (C6-C10)arylsulfonyl, (C2-C9)heterocycloalkyl, (C2-C9)heteroaryl, (C2-C9)heterocycloalkyl(C1-C6)alkyl, (C2-C9)heteroaryl(C1-C6)alkyl or R14R15N(C1-C6)alkyl wherein R14 and R15 are each independently (C1-C6)alkyl or (C1-C6)alkylcarbonyl;
  • R[0018] 4 is (R5)f(R6)g(C6-C10)aryl, (R5)f(R6)g(C3-C10)cycloalkyl, (R5)f(R7)h(C2-C9)heteroaryl, or (R5)f(R7)h(C2-C9)heterocycloalkyl,
  • wherein f is 1, 2, 3 or 4; [0019]
  • g and h are each independently 0, 1, 2 or 3; [0020]
  • R[0021] 5 is one to three groups independently selected from (C2-C9)heterocycloalkylcarbonyl, (C2-C9)heteroarylcarbonyl, (C2-C9)heteroaryl(C1-C6)alkylaminocarbonyl, (C2-C9)heterocycloalkyl(C1-C6)alkylaminocarbonyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylaminocarbonyl, ureido(C1-C6)alkylaminocarbonyl, (C1-C6)alkylureido(C1-C6)alkylaminocarbonyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylaminocarbonyl, halo(C1-C6)alkylaminocarbonyl, aminosulfonyl(C1-C6)alkylaminocarbonyl, (C1-C6)alkylaminosulfonyl(C1-C6)alkylaminocarbonyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylcarbonylamino, cyanoguanidino(C1-C6)alkylcarbonylamino, (C1-C6)alkylcyanoguanidino(C1-C6)alkylcarbonylamino, ((C1-C6)alkyl)2cyanoguanidino(C1-C6)alkylcarbonylamino, aminocarbonyl(C1-C6)alkylcarbonylamino, (C2-C9)heteroaryl(C1-C6)alkylcarbonylamino, (C2-C9)heterocycloalkyl(C1-C6)alkylcarbonylamino, aminosulfonyl(C1-C6)alkylcarbonylamino, hydroxy(C1-C6)alkylureido, amino(C1-C6)alkylureido, (C1-C6)alkylamino(C1-C6)alkylureido, ((C1-C6)alkyl)2amino(C1-C6)alkylureido, (C2-C9)heterocycloalkyl(C1-C6)alkylureido, (C2-C9)heteroaryl(C1-C6)alkylureido, aminosulfonyl(C1-C6)alkylureido, aminocarbonyl(C1-C6)alkylureido, (C1-C6)alkylaminocarbonyl(C1-C6)alkylureido, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkylureido, acetylamino(C1-C6)alkylureido, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylureido, halo(C1-C6)alkylsulfonylamino, amino(C1-C6)alkylsulfonylamino, (C1-C6)alkylamino(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2amino(C1-C6)alkylsulfonylamino, acetylamino(C1-C6)alkylsulfonylamino, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylsulfonylamino, ureido(C1-C6)alkylsulfonylamino, (C1-C6)alkylureido(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2ureido(C1-C6)alkylsulfonylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkylsulfonylamino, cyanoguanidino(C1-C6)alkylsulfonylamino, (C1-C6)alkylcyanoguanidino(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2cyanoguanidino(C1-C6)alkylsulfonylamino, aminocarbonyl(C1-C6)alkylsulfonylamino, (C1-C6)alkoxycarbonylamino(C1-C6)alkylsulfonylamino, aminosulfonylamino, (C1-C6)alkylaminosulfonylamino, ((C1-C6)alkyl)2aminosulfonylamino, aminocarbonyl(C1-C6)alkylamino(C1-C6)alkylsulfonylamino, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylsulfonylamino, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylsulfonylamino, cyanoguanidino, (C1-C6)alkylcyanoguanidino, ((C1-C6)alkyl)2cyanoguanidino, (C2-C9)heterocycloalkylcyanoguanidino, (C2-C9)heteroarylcyanoguanidino, (C2-C9)heterocycloalkyl(C1-C6)alkylcyanoguanidino, (C2-C9)heteroaryl(C1-C6)alkylcyanoguanidino, amino(C1-C6)alkylcyanoguanidino, (C1-C6)alkylamino(C1-C6)alkylcyanoguanidino, ((C1-C6)alkyl)2amino(C1-C6)alkylcyanoguanidino, aminocarbonyl(C1-C6)alkylcyanoguanidino, (C1-C6)alkylaminocarbonyl(C1-C6)alkylcyanoguanidino, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkylcyanoguanidino, aminocarbonyl(C1-C6)alkylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkylamino, (C1-C6)alkoxycarbonylamino(C1-C6)alkylamino, aminosulfonyl(C1-C6)alkylamino, (C2-C9)heteroaryl(C1-C6)alkylamino, acetylamino(C1-C6)alkylamino, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylamino, (C1-C6)alkoxycarbonyl(C1-C6)alkylamino(C1-C6)alkyl, cyano(C1-C6)alkylaminoalkyl, aminocarbonyl(C1-C6)alkylamino(C1-C6)alkyl, acetylamino(C1-C6)alkylamino(C1-C6)alkyl, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkylamino(C1-C6)alkyl, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylamino(C1-C6)alkyl, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylamino(C1-C6)alkyl, cyanoguanidino(C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkylcyanoguanidino(C1-C6)alkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2cyanoguanidino(C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylamino(C1-C6)alkyl, ureido(C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkylureido(C1-C6)alkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylamino(C1-C6)alkyl, aminocarbonyloxy(C1-C6)alkylamino(C1-C6)alkyl, aminocarbonyl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, aminosulfonyl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkyl, cyanoguanidino(C1-C6)alkylcarbonylamino(C1-C6)alkyl, cyano(C1-C6)alkylcarbonylamino(C1-C6)alkyl, amino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, hydroxy(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, aminocarbonyl(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C1-C6)alkylcarbonylamino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C2-C9)heterocycloalkyl(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C2-C9)heteroaryl(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, ureido(C1-C6)alkylureido(C1-C6)alkyl, (C1-C6)alkylureido(C1-C6)alkylureido(C1-C6)alkyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylureido(C1-C6)alkyl, cyanoguanidino(C1-C6)alkylureido(C1-C6)alkyl, halo(C1-C6)alkylsulfonylamino(C1-C6)alkyl, amino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, acetylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, ureido(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkylureido(C1-C6)alkylsulfonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, cyanoguanidino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkyl(cyanoguanidino)(C1-C6)alkylsulfonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2(cyanoguanidino)(C1-C6)alkylsulfonylamino(C1-C6)alkyl, aminocarbonyl(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, aminosulfonylamino(C1-C6)alkyl, (C1-C6)alkylaminosulfonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2aminosulfonylamino(C1-C6)alkyl, cyanoguanidino(C1-C6)alkyl, (C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, ((C1-C6)alkyl)2(cyanoguanidino)(C1-C6)alkyl, (C2-C9)heterocycloalkyl(cyanoguanidino)(C1-C6)alkyl, (C2-C9)heterocycloalkyl(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, (C2-C9)heterocycloalkyl(cyanoguanidino)amino, (C2-C9)heteroaryl(cyanoguanidino)(C1-C6)alkyl, (C2-C9)heteroaryl(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, amino(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, aminocarbonyl(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, aminosulfonyl, (C1-C6)alkylaminosulfonyl, ((C1-C6)alkyl)2aminosulfonyl, (C2-C9)heterocycloalkylsulfonyl, amino(C1-C6)alkylaminosulfonyl, (C1-C6)alkylamino(C1-C6)alkylaminosulfonyl, ((C1-C6)alkyl)2amino(C1-C6)alkylaminosulfonyl, (C2-C9)heteroarylaminosulfonyl, hydroxy(C1-C6)alkylaminosulfonyl, (C1-C6)alkoxy(C1-C6)alkylaminosulfonyl, ureido(C1-C6)alkylaminosulfonyl, (C1-C6)alkylureido(C1-C6)alkylaminosulfonyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylaminosulfonyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylaminosulfonyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkylaminosulfonyl, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylaminosulfonyl, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylaminosulfonyl, aminocarbonyl(C1-C6)alkylaminosulfonyl, cyanoguanidino(C1-C6)alkylaminosulfonyl, (C2-C9)heteroaryl(C1-C6)alkylaminosulfonyl, (C2-C9)heterocycloalkylaminosulfonyl, R6 is one to three groups independently selected from hydrogen, hydroxy, hydroxysulfonyl, halo, (C1-C6)alkyl, mercapto, mercapto(C1-C6)alkyl, (C1-C6)alkylthio, (C1-C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, (C6-C10)arylsulfonyl, (C1-C6)alkylthio(C1-C6)alkyl, (C1-C6)alkylsulfinyl(C1-C6)alkyl, (C1-C6)alkylsulfonyl(C1-C6)alkyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkoxy, (C6-C10)aryloxy, halo(C1-C6)alkyl, trifluoro(C1-C6)alkyl, formyl, formyl(C1-C6)alkyl, nitro, nitroso, cyano, (C6-C10)aryl(C1-C6)alkoxy, halo(C1-C6)alkoxy, trifluoro(C1-C6)alkoxy, amino(C1-C6)alkoxy, (C3-C10)cycloalkyl, (C3-C10)cycloalkyl(C1-C6)alkyl, hydroxy(C3-C10)cycloalkyl(C1-C6)alkyl, (C3-C10)cycloalkylamino, (C3-C10)cycloalkylamino(C1-C6)alkyl, cyano(C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl, (C6-C10)aryl(C2-C6)alkenyl, hydroxy(C1-C6)alkyl, (hydroxy) (C6-C10)aryl(C1-C6)alkyl, ((C1-C6)alkylamino)(C6-C10)aryl(C1-C6)alkyl, hydroxy(C1-C6)alkylthio(C1-C6)alkyl, hydroxy(C2-C6)alkenyl, hydroxy(C2-C6)alkenyl, hydroxy(C2-C6)alkynyl, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxy(C6-C10)aryl(C1-C6)alkyl, aryloxy(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkoxy(C1-C6)alkyl, amino, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, (C6-C10)arylamino, (C6-C10)aryl(C1-C6)alkylamino, amino(C1-C6)alkylamino, (C2-C9)heterocycloalkylamino, (C2-C9)heteroarylamino, (C3-C10)cycloalkyl(C1-C6)alkyl)amino, (C1-C6)alkylcarbonylamino, (C1-C6)alkoxycarbonylamino, (C2-C6)alkenylcarbonylamino, (C3-C10)cycloalkylcarbonylamino, (C6-C10)arylcarbonylamino, (C2-C9)heterocycloalkylcarbonylamino, halo(C1-C6)alkylcarbonylamino, (C1-C6)alkoxy(C1-C6)alkylcarbonylamino, (C1-C6)alkoxycarbonyl(C1-C6)alkylcarbonylamino, ((C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino, ((C1-C6)alkoxycarbonyl)((C1-C6)alkyl)amino, (C1-C6)alkylsulfonylamino, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkyl, hydroxy(C1-C6)alkylamino(C1-C6)alkyl, (C6-C10)arylamino(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C6-C10)arylcarbonylamino(C1-C6)alkyl, ((C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino(C1-C6)alkyl, C3-C10)cycloalkyl(C1-C6)alkyl)amino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonyl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, ((C1-C6)alkoxycarbonyl)((C1-C6)alkyl)amino(C1-C6)alkyl, (C1-C6)alkylsulfonylamino(C1-C6)alkyl, ((C1-C6)alkylsulfonyl)((C1-C6)alkyl)amino(C1-C6)alkyl, (C6-C10)arylsulfonylamino(C1-C6)alkyl, ((C6-C10)arylsulfonyl)((C1-C6)alkyl)amino(C1-C6)alkyl, (C2-C9)heterocycloalkylamino(C1-C6)alkyl, (C2-C9)heteroarylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C6-C10)aryl(C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C6-C10)arylcarbonyl, (C6-C10)aryl(C1-C6)alkylcarbonyl, hydroxy(C1-C6)alkoxycarbonyl, (C1-C6)alkoxycarbonyl(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkoxycarbonyl(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkylcarbonyloxy(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonyloxy(C1-C6)alkyl, (C1-C6)alkylcarbonyl(C1-C6)alkyl, (C6-C10)arylcarbonyl(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylcarbonyl(C1-C6)alkyl, aminocarbonyl, (C1-C6)alkylaminocarbonyl, ((C1-C6)alkyl)2aminocarbonyl, (C6-C10)arylaminocarbonyl, (C6-C10)aryl(C1-C6)alkylaminocarbonyl, (aminocarbonyl(C1-C6)alkylaminocarbonyl, ((C1-C6)alkylaminocarbonyl(C1-C6)alkylaminocarbonyl, ((C1-C6)alkoxycarbonyl(C1-C6)alkylaminocarbonyl, (amino(C1-C6)alkyl)aminocarbonyl, (hydroxy(C1-C6)alkylaminocarbonyl, aminocarbonyl(C1-C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkyl, (C6-C10)arylaminocarbonyl(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylaminocarbonyl(C1-C6)alkyl, amidino, hydroxyamidino, guanidino, ureido, (C1-C6)alkylureido, (C6-C10)arylureido, ((C6-C10)aryl)2ureido, (C6-C10)aryl(C1-C6)alkylureido, halo(C1-C6)alkylureido, ((C1-C6)alkyl)((C6-C10)aryl)ureido, ((C1-C6)alkyl)2ureido, halo(C1-C6)alkylcarbonylureido, ureido(C1-C6)alkyl, (C1-C6)alkylureido(C1-C6)alkyl, ((C1-C6)alkyl)2ureido(C1-C6)alkyl, (C6-C10)arylureido(C1-C6)alkyl, (C6-C10)aryl)2ureido(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylureido(C1-C6)alkyl, halo(C1-C6)alkylureido(C1-C6)alkyl, (halo(C1-C6)alkyl)((C1-C6)alkyl)ureido(C1-C6)alkyl, ((C1-C6)alkoxycarbonyl(C1-C6)alkyl)ureido(C1-C6)alkyl, glycinamido, (C1-C6)alkylglycinamido, aminocarbonylglycinamido, (C1-C6)alkoxy(C1-C6)alkylcarbonylglycinamido, (aminocarbonyl)((C1-C6)alkyl)glycinamido, ((C1-C6)alkoxycarbonyl(C1-C6)alkylcarbonyl)((C1-C6)alkyl)glycinamido, ((C1-C6)alkoxycarbonylamino(C1-C6)alkylcarbonyl)glycinamido, (C6-C10)arylcarbonylglycinamido, ((C6-C10)arylcarbonyl)((C1-C6)alkyl)glycinamido, ((C6-C10)aryl(C1-C6)alkylaminocarbonyl)glycinamido, (C6-C10)aryl(C1-C6)alkylaminocarbonyl)((C1-C6)alkyl)glycinamido, (C6-C10)arylaminocarbonylglycinamido, ((C6-C10)arylaminocarbonyl)((C1-C6)alkyl)glycinamido, glycinamido(C1-C6)alkyl, alaninamido, (C1-C6)alkylalaninamido, alaninamido(C1-C6)alkyl, (C2-C9)heteroaryl, (C2-C9)heterocycloalkyl, (C2-C9)heteroaryl(C1-C6)alkyl and (C2-C9)heterocycloalkyl(C1-C6)alkyl;
  • R[0022] 7 is one to three groups independently selected from hydrogen, hydroxy, halo, (C1-C6)alkyl, (C1-C6)alkylsulfonyl, (C6-C10)arylsulfonyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkoxy, halo(C1-C6)alkyl, fomyl, nitro, cyano, halo(C1-C6)alkoxy, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl, amino, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, (C6-C10)arylamino, (C6-C10)aryl(C1-C6)alkylamino, (C1-C6)alkylcarbonylamino, (C1-C6)alkoxycarbonylamino, (C2-C6)alkenylcarbonylamino, cycloalkylcarbonylamino, (C6-C10)arylcarbonylamino, halo(C1-C6)alkylcarbonylamino, (C1-C6)alkoxy(C1-C6)alkylcarbonylamino, (C1-C6)alkoxycarbonyl(C1-C6)alkylcarbonylamino, ((C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino, ((C1-C6)alkoxycarbonyl)((C1-C6)alkyl)amino, (C1-C6)alkylsulfonylamino, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkyl, (C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C6-C10)arylcarbonylamino(C1-C6)alkyl, ((C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C6-C10)aryl(C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C6-C10)arylcarbonyl, (C6-C10)aryl(C1-C6)alkylcarbonyl, aminocarbonyl, (C1-C6)alkylaminocarbonyl, ((C1-C6)alkyl)2aminocarbonyl, (C6-C10)arylaminocarbonyl, aminocarbonyl(C1-C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkyl, (C6-C10)arylaminocarbonyl(C1-C6)alkyl, guanidino, ureido, (C1-C6)alkylureido, ureido(C1-C6)alkyl, (C1-C6)alkylureido(C1-C6)alkyl, and glycinamido;
  • R[0023] 9 and R10 are each independently selected from the group consisting of hydrogen, (C1-C6)alkyl, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl, (C1-C6)alkylcarbonyl, (C1-C6)alkylcarbonyl(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylcarbonyl, (C6-C10)aryl(C1-C6)alkylcarbonyl(C1-C6)alkyl, aminocarbonyl, (C1-C6)alkylaminocarbonyl, ((C1-C6)alkyl)2aminocarbonyl and (C1-C6)alkoxycarbonyl; and R11 and R12 are each independently selected from the group consisting of hydrogen, (C1-C6)alkyl, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl, hydroxy, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, amino, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, (C1-C6)alkylcarbonylamino, (C3-C8)cycloalkylcarbonylamino, (C3-C8)cycloalkyl(C1-C6)alkylcarbonylamino, (C1-C6)alkoxycarbonylamino, (C1-C6)alkylsulfonylamino, (C6-C10)arylcarbonylamino, (C1-C6)alkoxycarbonyl(C1-C6)alkylcarbonylamino, (C6-C10)aryl(C1-C6)alkylcarbonylamino, ((C6-C10)aryl(C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino, (C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C3-C8)cycloalkylcarbonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkyl, (C2-C9)heterocycloalkylcarbonylamino(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C2-C9)heteroarylcarbonylamino(C1-C6)alkyl, (C6-C10)arylsulfonylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkyl, aminocarbonylamino, (C1-C6)alkylaminocarbonylamino, halo(C1-C6)alkylaminocarbonylamino, ((C1-C6)alkyl)2aminocarbonylamino, aminocarbonylamino(C1-C6)alkyl, (C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonylamino(C1-C6)alkyl, halo(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkyl, carboxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl(C1-C6)alkyl, aminocarbonyl(C1-C6)alkyl and (C1-C6)alkylaminocarbonyl(C1-C6)alkyl.
  • Preferred compounds of formula I include those wherein R[0024] 1 is hydrogen, halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C1-C6)alkyl, hydroxy or (C1-C6)alkylcarbonyloxy.
  • Other preferred compounds of formula I include those wherein R[0025] 2 and R3 are each independently selected from (C1-C6)alkyl, (C3-C8)cycloalkyl, amino(C1-C6)alkyl, amino(C3-C8)cycloalkyl, (C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkylamino(C3-C8)cycloalkyl, hydroxy(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkyl, ureido(C1-C6)alkyl, (C1-C6)alkyureido(C1-C6)alkyl, (C2-C9)heteroaryl(C1-C6)alkyl or (C2-C9)heterocycloalkyl(C1-C6)alkyl.
  • Other preferred compounds of formula I include those wherein c is 1; X is C(O); d is 1; Y is CH[0026] 2; e is 1; and Z is oxygen.
  • Other preferred compounds of formula I include those wherein c is 1; X is C(O); d is 2; Y is ethylene; and e is 0. [0027]
  • Other preferred compounds of formula I include those wherein c is 1; X is C(O); d is 1; Y is CH[0028] 2; e is 1; and Z is NR9 wherein R9 is hydrogen or (C1-C6)alkyl.
  • Other preferred compounds of formula I include those wherein c is 1; X is CH[0029] 2; d is 1; Y is CH2; e is 1; and Z is oxygen.
  • Other preferred compounds of formula I include those wherein c is 1; X is CH[0030] 2; d is 2; Y is ethylene; and e is 0.
  • Other preferred compounds of formula I include those wherein c is 1; X is CH[0031] 2; d is 1; Y is CH2; e is 1; and Z is NR9 wherein R9 is hydrogen or (C1-C6)alkyl.
  • Other preferred compounds of formula I include those wherein c is 1; X is C(O); d is 1; Y is CHR[0032] 8 wherein R8 is NR9R10; R9 and R10 are each independently hydrogen, (C1-C6)alkyl or (C1-C6)alkylcarbonyl; e is 1; and Z is oxygen.
  • Other preferred compounds of formula I include those wherein c is 1; X is C(O); d is 1; Y is CHR[0033] 8 wherein R8 is NR9R10; R9 and R10 are each independently hydrogen, (C1-C6)alkyl or (C1-C6)alkylcarbonyl; e is 1; and Z is CR11R12 wherein R11 and R12 are hydrogen.
  • Other preferred compounds of formula I include those wherein c is 1; X is C(O); d is 1; Y is CHR[0034] 8 wherein R8 is NR9R10; R9 and R10 are each independently hydrogen, (C1-C6)alkyl or (C1-C6)alkylcarbonyl; e is 1; and Z is NR9 wherein R9 is hydrogen or (C1-C6)alkyl.
  • Other preferred compounds of formula I include those wherein c is 1; X is CH[0035] 2; d is 1; Y is CHR8 wherein R8 is NR9R10; R9 and R10 are each independently hydrogen, (C1-C6)alkyl or (C1-C6)alkylcarbonyl; e is 1; and Z is oxygen.
  • Other preferred compounds of formula I include those wherein c is 1; X is CH[0036] 2; d is 1; Y is CHR8 wherein R8 is NR9R10; R9 and R10 are each independently hydrogen, (C1-C6)alkyl or (C1-C6)alkylcarbonyl; e is 1; and Z is CR11R12 wherein R11 and R12 are hydrogen.
  • Other preferred compounds of formula I include those wherein c is 1; X is CH[0037] 2; d is 1; Y is CHR8 wherein R8 is NR9R10; R9 and R10 are each independently hydrogen, (C1-C6)alkyl or (C1-C6)alkylcarbonyl; e is 1; and Z is NR9 wherein R9 is hydrogen or (C1-C6)alkyl.
  • Other preferred compounds of formula I include those wherein R[0038] 4 is (R5)f(R6)g(C6-C10)aryl or (R5)f(R7)h(C2-C9)heteroaryl wherein f, g and h are independently 1 or 2.
  • Other preferred compounds of formula I include those wherein R[0039] 5 is (C2-C9)heterocycloalkylcarbonyl, (C2-C9)heteroarylcarbonyl, (C2-C9)heteroaryl(C1-C6)alkylaminocarbonyl, (C2-C9)heterocycloalkyl(C1-C6)alkylaminocarbonyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylaminocarbonyl, ureido(C1-C6)alkylaminocarbonyl, (C1-C6)alkylureido(C1-C6)alkylaminocarbonyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylaminocarbonyl, aminosulfonyl(C1-C6)alkylaminocarbonyl or (C1-C6)alkylaminosulfonyl(C1-C6)alkylaminocarbonyl.
  • Other preferred compounds of formula I include those wherein R[0040] 5 is (C1-C6)alkylsulfonylamino(C1-C6)alkylcarbonylamino, cyanoguanidino(C1-C6)alkylcarbonylamino, (C1-C6)alkylcyanoguanidino(C1-C6)alkylcarbonylamino, ((C, —C6)alkyl)2cyanoguanidino(C1-C6)alkylcarbonylamino, aminocarbonyl(C1-C6)alkylcarbonylamino, (C2-C9)heteroaryl(C1-C6)alkylcarbonylamino, (C2-C9)heterocycloalkyl(C1-C6)alkylcarbonylamino, or aminosulfonyl(C1-C6)alkylcarbonylamino.
  • Other preferred compounds of formula I include those wherein R[0041] 5 is amino(C1-C6)alkylureido, (C1-C6)alkylamino(C1-C6)alkylureido, ((C1-C6)alkyl)2amino(C1-C6)alkylureido, (C2-C9)heterocycloalkyl(C1-C6)alkylureido, (C2-C9)heteroaryl(C1-C6)alkylureido, aminosulfonyl(C1-C6)alkylureido, aminocarbonyl(C1-C6)alkylureido, (C1-C6)alkylaminocarbonyl(C1-C6)alkylureido, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkylureido, acetylamino(C1-C6)alkylureido, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylureido.
  • Other preferred compounds of formula I include those wherein R[0042] 5 is amino(C1-C6)alkylsulfonylamino, (C1-C6)alkylamino(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2amino(C1-C6)alkylsulfonylamino, acetylamino(C1-C6)alkylsulfonylamino, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylsulfonylamino, ureido(C1-C6)alkylsulfonylamino, (C1-C6)alkylureido(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2ureido(C1-C6)alkylsulfonylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkylsulfonylamino, cyanoguanidino(C1-C6)alkylsulfonylamino, (C1-C6)alkylcyanoguanidino(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2cyanoguanidino(C1-C6)alkylsulfonylamino, aminocarbonyl(C1-C6)alkylsulfonylamino, (C1-C6)alkoxycarbonylamino(C1-C6)alkylsulfonylamino, aminosulfonylamino, (C1-C6)alkylaminosulfonylamino, ((C1-C6)alkyl)2aminosulfonylamino, aminocarbonyl(C1-C6)alkylamino(C1-C6)alkylsulfonylamino, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylsulfonylamino or (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylsulfonylamino.
  • Other preferred compounds of formula I include those wherein R[0043] 5 is cyanoguanidino, (C1-C6)alkylcyanoguanidino, ((C1-C6)alkyl)2cyanoguanidino, (C2-C9)heterocycloalkylcyanoguanidino, (C2-C9)heteroarylcyanoguanidino, (C2-C9)heterocycloalkyl(C1-C6)alkylcyanoguanidino, (C2-C9)heteroaryl(C1-C6)alkylcyanoguanidino, amino(C1-C6)alkylcyanoguanidino, (C1-C6)alkylamino(C1-C6)alkylcyanoguanidino, ((C1-C6)alkyl)2amino(C1-C6)alkylcyanoguanidino, aminocarbonyl(C1-C6)alkylcyanoguanidino, (C1-C6)alkylaminocarbonyl(C1-C6)alkylcyanoguanidino or ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkylcyanoguanidino.
  • Other preferred compounds of formula I include those wherein R[0044] 5 is aminocarbonyl(C1-C6)alkylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkylamino, (C1-C6)alkoxycarbonylamino(C1-C6)alkylamino, aminosulfonyl(C1-C6)alkylamino, (C2-C9)heteroaryl(C1-C6)alkylamino, acetylamino(C1-C6)alkylamino or (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylamino.
  • Other preferred compounds of formula I include those wherein R[0045] 5 is cyano(C1-C6)alkylaminoalkyl or aminocarbonyl(C1-C6)alkylamino(C1-C6)alkyl.
  • Other preferred compounds of formula I include those wherein R[0046] 5 is acetylamino(C1-C6)alkylamino(C1-C6)alkyl, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkylamino(C1-C6)alkyl, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylamino(C1-C6)alkyl, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylamino(C1-C6)alkyl, cyanoguanidino(C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkylcyanoguanidino(C1-C6)alkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2cyanoguanidino(C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylamino(C1-C6)alkyl, ureido(C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkylureido(C1-C6)alkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylamino(C1-C6)alkyl or aminocarbonyloxy(C1-C6)alkylamino(C1-C6)alkyl.
  • Other preferred compounds of formula I include those wherein R[0047] 5 is acetylamino(C1-C6)alkylcarbonylamino(C1-C6)alkyl, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylcarbonylamino(C1-C6)alkyl, aminocarbonyl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, aminosulfonyl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkyl, cyanoguanidino(C1-C6)alkylcarbonylamino(C1-C6)alkyl or cyano(C1-C6)alkylcarbonylamino(C1-C6)alkyl.
  • Other preferred compounds of formula I include those wherein R[0048] 5 is amino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkylaminocarbonyl amino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, aminocarbonyl(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C1-C6) alkylcarbonylamino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonyl amino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C2-C9)heterocycloalkyloxycarbonyl amino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C2-C9)heterocycloalkyl(C1-C6)alkylaminocarbony lamino(C1-C6)alkyl, (C2-C9)heteroaryl(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, ureido(C1-C6)alkylureido(C1-C6)alkyl, (C, —C6)alkylureido(C1-C6)alkylureido(C1-C6)alkyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylureido(C1-C6)alkyl or cyanoguanidino(C1-C6)alkylureido(C1-C6)alkyl. Other preferred compounds of formula I include those wherein R5 is amino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, acetylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, ureido(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkylureido(C1-C6)alkylsulfonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, cyanoguanidino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkyl(cyanoguanidino)(C1-C6)alkylsulfonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2(cyanoguanidino)(C1-C6)alkylsulfonylamino(C1-C6)alkyl, aminocarbonyl(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, aminosulfonylamino(C1-C6)alkyl, (C1-C6)alkylaminosulfonylamino(C1-C6)alkyl or ((C1-C6)alkyl)2aminosulfonylamino(C1-C6)alkyl.
  • Other preferred compounds of formula I include those wherein R[0049] 5 is cyanoguanidino(C1-C6)alkyl, (C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, ((C1-C6)alkyl)2(cyanoguanidino)(C1-C6)alkyl, (C2-C9)heterocycloalkyl(cyanoguanidino)(C1-C6)alkyl, (C2-C9)heteroaryl(cyanoguanidino)(C1-C6)alkyl, (C2-C9)heterocycloalkyl(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, (C2-C9)heteroaryl(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, amino(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, aminocarbonyl(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl or ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl.
  • Other preferred compounds of formula I include those wherein R[0050] 5 is (C2-C9)heterocycloalkylsulfonyl, amino(C1-C6)alkylaminosulfonyl, (C1-C6)alkylamino(C1-C6)alkylaminosulfonyl, ((C1-C6)alkyl)2amino(C1-C6)alkylaminosulfonyl, (C2-C9)heteroarylaminosulfonyl, ureido(C1-C6)alkylaminosulfonyl, (C1-C6)alkylureido(C1-C6)alkylaminosulfonyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylaminosulfonyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylaminosulfonyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkylaminosulfonyl, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylaminosulfonyl, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylaminosulfonyl, aminocarbonyl(C1-C6)alkylaminosulfonyl, cyanoguanidino(C1-C6)alkylaminosulfonyl, (C2-C9)heteroaryl(C1-C6)alkylaminosulfonyl, (C2-C9)heterocycloalkylaminosulfonyl, Other preferred compounds of formula I include those wherein R5 is halo(C1-C6)alkylaminocarbonyl, hydroxy(C1-C6)alkylureido, halo(C1-C6)alkylsulfonylamino, (C1-C6)alkoxycarbonyl(C1-C6)alkylamino(C1-C6)alkyl, hydroxy(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, halo(C1-C6)alkylsulfonylamino(C1-C6)alkyl, aminosulfonyl, (C1-C6)alkylaminosulfonyl, ((C1-C6)alkyl)2aminosulfonyl, hydroxy(C1-C6)alkylaminosulfonyl, and (C1-C6)alkoxy(C1-C6)alkylaminosulfonyl.
  • Other preferred compounds of formula I include those wherein R[0051] 6 and R7 are each independently halo, halo(C1-C6)alkyl, (C1-C6)alkyl, (C1-C6)alkoxy, trifluoromethyl, trifluoromethoxy, hydroxy, aminocarbonyl, cyano, ureido, (C1-C6)alkylsulfonylamino, (C1-C6)alkoxycarbonylamino or glycinamino.
  • The present invention also relates to the pharmaceutically acceptable acid addition salts of compounds of the formula I. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [, 1,1′-methylene-bis-(2-hydroxy-3-naphthoate)]salts. [0052]
  • The invention also relates to base addition salts of formula I. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of formula I that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (ea., potassium and sodium) and alkaline earth metal cations (eq., calcium and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines. [0053]
  • The compounds of this invention may contain olefin-like double bonds. When such bonds are present, the compounds of the invention exist as cis and trans configurations and as mixtures thereof. [0054]
  • The present invention also relates to compounds of formula I wherein any of the hydrogens may optionally be replaced by deuterium. [0055]
  • Unless otherwise indicated, the alkyl, alkenyl and alkynyl groups referred to herein, as well as the alkyl moieties of other groups referred to herein (e.g., alkoxy), may be linear or branched, and they may also be cyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl) or be linear or branched and contain cyclic moieties. Unless otherwise indicated, halogen includes fluorine, chlorine, bromine, and iodine. [0056]
  • (C[0057] 3-C10)Cycloalkyl when used herein refers to cycloalkyl groups containing zero to two levels of unsaturation such as cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, 1,3-cyclohexadiene, cycloheptyl, cycloheptenyl, bicyclo[3.2.1]octane, norbornanyl etc.
  • (C[0058] 2-C9)Heterocycloalkyl when used herein refers to pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyranyl, pyranyl, thiopyranyl, aziridinyl, oxiranyl, methylenedioxyl, chromenyl, barbituryl, isoxazolidinyl, 1,3-oxazolidin-3-yl, isothiazolidinyl, 1,3-thiazolidin-3-yl, 1,2-pyrazolidin-2-yl, 1,3-pyrazolidin-1-yl, piperidinyl, thiomorpholinyl, 1,2-tetrahydrothiazin-2-yl, 1,3-tetrahydrothiazin-3-yl, tetrahydrothiadiazinyl, morpholinyl, 1,2-tetrahydrodiazin-2-yl, 1,3-tetrahydrodiazin-1-yl, tetrahydroazepinyl, piperazinyl, chromanyl, etc.
  • (C[0059] 2-C9)Heteroaryl when used herein refers to furyl, thienyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, 1,3,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-oxadiazolyl, 1,3,5-thiadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, 1,3,5-triazinyl, pyrazolo[3,4-b]pyridinyl, cinnolinyl, pteridinyl, purinyl, 6,7-dihydro-5H-[1]pyrindinyl, benzo[b]thiophenyl, 5, 6, 7, 8-tetrahydro-quinolin-3-yl, benzoxazolyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, thianaphthenyl, isothianaphthenyl, benzofuranyl, isobenzofuranyl, isoindolyl, indolyl, indolizinyl, indazolyl, isoquinolyl, quinolyl, phthalazinyl, quinoxalinyl, quinazolinyl, benzoxazinyl; etc.
  • Aryl when used herein refers to phenyl or naphthyl. [0060]
  • The term “ureido”, as used herein, refers to an “amino-carbonyl-amino” moiety. [0061]
  • The term “acetyl”, as used herein, refers to an “alkyl-carbonyl” moiety wherein alkyl is defined as above. [0062]
  • The term “cyanoguanidino”, as used herein, refers to a functional group having the following formula [0063]
    Figure US20040058932A1-20040325-C00003
  • The term “(C[0064] 2-C9)heterocycloalkyl(C═N—CN)amino”, as used herein refers to a functional group having the following formula
    Figure US20040058932A1-20040325-C00004
  • wherein “HET” refers to a (C[0065] 2-C9)heterocyloalkyl or (C2-C9)heteroaryl group and the nigrogen of said group is the place of attachment.
  • The term “mercapto”, as used herein, refers to a “HS-” moeity. [0066]
  • The compounds of this invention include all conformational isomers (e.g., cis and trans isomers) and all optical isomers of compounds of the formula I (e.g., enantiomers and diastereomers), as well as racemic, diastereomeric and other mixtures of such isomers. [0067]
  • The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases, rheumatoid arthritis, recent onset type I diabetes, lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, vasculitis, acute and chronic inflammatory conditions, osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, glomerulonephritis, allergic conditions, asthma, atopic dermatitis, infection associated with inflammation, viral inflammation, influenza, hepatitis, Guillian-Barre, chronic bronchitis, xeno-transplantation, chronic and acute transplantation tissue rejection, chronic and acute organ transplant rejection, atherosclerosis, restenosis, HIV infectivity, granulomatous diseases, sarcoidosis, leprosy and tuberculosis and sequelae associated with certain cancers such as multiple myeloma. Compounds in this series may also limit the production of cytokines at inflammatory sites, including but not limited to TNF and IL-1, as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1, including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1, HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex). They may also provide benefit for the sequelae associated with infection where such infection induces production of detrimental inflammatory cytokines such as TNF e.g, fungal meningitis, joint tissue damage, hyperplasia, pannus formation and bone resorption, psoriatic arthritis, hepatic failure, bacterial meningitis, Kawasaki syndrome, myocardial infarction, acute liver failure, lyme disease, septic shock, cancer, trauma, and malaria in a mammal, preferably a human, comprising an amount of a compound of the formula I or a pharmaceutically acceptable salt thereof effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier. [0068]
  • The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by inhibiting chemokine binding to the receptor CCR1 in a mammal, preferably a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier. Examples of such disorders and conditions are those enumerated in the preceding paragraph. [0069]
  • The present invention also relates to a method for treating or preventing a disorder or condition selected from autoimmune diseases, rheumatoid arthritis, recent onset type I diabetes, lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, vasculitis, acute and chronic inflammatory conditions, osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, glomerulonephritis, allergic conditions, asthma, atopic dermatitis, infection associated with inflammation, viral inflammation, influenza, hepatitis, Guillian-Barre, chronic bronchitis, xeno-transplantation, chronic and acute transplantation tissue rejection, chronic and acute organ transplant rejection, atherosclerosis, restenosis, HIV infectivity, granulomatous diseases, sarcoidosis, leprosy and tuberculosis and sequelae associated with certain cancers such as multiple myeloma. Compounds in this series may also limit the production of cytokines at inflammatory sites, including but not limited to TNF and IL-1, as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1, including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1, HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex). They may also provide benefit for the sequelae associated with infection where such infection induces production of detrimental inflammatory cytokines such as TNF e.g, fungal meningitis, joint tissue damage, hyperplasia, pannus formation and bone resorption, psoriatic arthritis, hepatic failure, bacterial meningitis, Kawasaki syndrome, myocardial infarction, acute liver failure, lyme disease, septic shock, cancer, trauma, and malaria in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition. [0070]
  • The present invention also relates to a method for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition. [0071]
  • The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases, rheumatoid arthritis, recent onset type I diabetes, lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, vasculitis, acute and chronic inflammatory conditions, osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, glomerulonephritis, allergic conditions, asthma, atopic dermatitis, infection associated with inflammation, viral inflammation, influenza, hepatitis, Guillian-Barre, chronic bronchitis, xeno-transplantation, chronic and acute transplantation tissue rejection, chronic and acute organ transplant rejection, atherosclerosis, restenosis, HIV infectivity, granulomatous diseases, sarcoidosis, leprosy and tuberculosis and sequelae associated with certain cancers such as multiple myeloma. Compounds in this series may also limit the production of cytokines at inflammatory sites, including but not limited to TNF and IL-1, as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1, including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1, HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex). They may also provide benefit for the sequelae associated with infection where such infection induces production of detrimental inflammatory cytokines such as TNF e.g, fungal meningitis, joint tissue damage, hyperplasia, pannus formation and bone resorption, psoriatic arthritis, hepatic failure, bacterial meningitis, Kawasaki syndrome, myocardial infarction, acute liver failure, lyme disease, septic shock, cancer, trauma, and malaria in a mammal, preferably a human, comprising a CCR1 receptor antagonizing effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. [0072]
  • The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, preferably a human, comprising a CCR1 receptor antagonizing effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. [0073]
  • The present invention also relates to a method for treating or preventing a disorder or condition selected from autoimmune diseases, rheumatoid arthritis, recent onset type I diabetes, lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, vasculitis, acute and chronic inflammatory conditions, osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, glomerulonephritis, allergic conditions, asthma, atopic dermatitis, infection associated with inflammation, viral inflammation, influenza, hepatitis, Guillian-Barre, chronic bronchitis, xeno-transplantation, chronic and acute transplantation tissue rejection, chronic and acute organ transplant rejection, atherosclerosis, restenosis, HIV infectivity, granulomatous diseases, sarcoidosis, leprosy and tuberculosis and sequelae associated with certain cancers such as multiple myeloma. Compounds in this series may also limit the production of cytokines at inflammatory sites, including but not limited to TNF and IL-1, as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1, including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1, HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex). They may also provide benefit for the sequelae associated with infection where such infection induces production of detrimental inflammatory cytokines such as TNF e.g, fungal meningitis, joint tissue damage, hyperplasia, pannus formation and bone resorption, psoriatic arthritis, hepatic failure, bacterial meningitis, Kawasaki syndrome, myocardial infarction, acute liver failure, lyme disease, septic shock, cancer, trauma, and malaria in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention a CCR1 receptor antagonizing effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof. [0074]
    • DETAILED DESCRIPTION OF THE INVENTION
  • The following reaction Schemes illustrate the preparation of the compounds of the present invention. Unless otherwise indicated a, b, c, d, e, j, R1, R[0075] 2, R3 and R4 in the reaction Schemes and the discussion that follow are defined as above.
  • R[0076] 16 and R17 together with the nitrogen to which they are attached is selected from the group consisting of amino, amino(C1-C6)alkylcarbonylamino, (C1-C6)alkylamino(C1-C6)alkylcarbonylamino, ((C1-C6)alkyl)2amino(C1-C6)alkylcarbonylamino, acetylamino(C1-C6)alkylcarbonylamino, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylcarbonylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkylcarbonylamino, cyanoguanidino(C1-C6)alkylcarbonylamino, (C1-C6)alkylcyanoguanidino(C1-C6)alkylcarbonylamino, ((C1-C6)alkyl)2cyanoguanidino(C1-C6)alkylcarbonylamino, aminocarbonyl(C1-C6)alkylcarbonylamino, aminocarbonylamino(C1-C6)alkylcarbonylamino, (C1-C6)alkylaminocarbonylamino(C1-C6)alkylcarbonylamino, ((C1-C6)alkyl)2aminocarbonylamino(C1-C6)alkylcarbonylamino, (C2-C9)heteroaryl(C1-C6)alkylcarbonylamino, (C2-C9)heterocycloalkyl(C1-C6)alkylcarbonylamino, aminosulfonyl(C1-C6)alkylcarbonylamino, hydroxy(C1-C6)alkylureido, (amino(C1-C6)alkylureido, (C1-C6)alkylamino(C1-C6)alkylureido, ((C1-C6)alkyl)2amino(C1-C6)alkylureido, (C2-C9)heterocycloalkyl(C1-C6)alkylureido, (C2-C9)heteroaryl(C1-C6)alkylureido, aminosulfonyl(C1-C6)alkylureido, aminocarbonyl(C1-C6)alkylureido, (C1-C6)alkylaminocarbonyl(C1-C6)alkylureido, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkylureido, acetylamino(C1-C6)alkylureido, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylureido, carboxy(C1-C6)alkylureido, halo(C1-C6)alkylsulfonylamino, amino(C1-C6)alkylsulfonylamino, (C1-C6)alkylamino(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2amino(C1-C6)alkylsulfonylamino, acetylamino(C1-C6)alkylsulfonylamino, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylsulfonylamino, ureido(C1-C6)alkylsulfonylamino, (C1-C6)alkylureido(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2ureido(C1-C6)alkylsulfonylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkylsulfonylamino, cyanoguanidino(C1-C6)alkylsulfonylamino, (C1-C6)alkylcyanoguanidino(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2cyanoguanidino(C1-C6)alkylsulfonylamino, aminocarbonyl(C1-C6)alkylsulfonylamino, (C1-C6)alkoxycarbonylamino(C1-C6)alkylsulfonylamino, aminosulfonylamino, (C1-C6)alkylaminosulfonylamino, ((C1-C6)alkyl)2aminosulfonylamino, aminocarbonyl(C1-C6)alkylamino(C1-C6)alkylsulfonylamino, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylsulfonylamino (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylsulfonylamino, cyanoguanidino, (C1-C6)alkylcyanoguanidino, ((C1-C6)alkyl)2cyanoguanidino, (C2-C9)heterocycloalkylcyanoguanidino, (C2-C9)heteroarylcyanoguanidino, (C2-C9)heterocycloalkyl(C1-C6)alkylcyanoguanidino, (C2-C9)heteroaryl(C1-C6)alkylcyanoguanidino, amino(C1-C6)alkylcyanoguanidino, (C1-C6)alkylamino(C1-C6)alkylcyanoguanidino, ((C1-C6)alkyl)2amino(C1-C6)alkylcyanoguanidino, aminocarbonyl(C1-C6)alkylcyanoguanidino, (C1-C6)alkylaminocarbonyl(C1-C6)alkylcyanoguanidino, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkylcyanoguanidino, hydroxy(C1-C6)alkylamino, aminocarbonyl(C1-C6)alkylamino, carboxy(C1-C6)alkylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkylamino, (C1-C6)alkoxycarbonylamino(C1-C6)alkylamino, aminosulfonyl(C1-C6)alkylamino, (C2-C9)heteroaryl(C1-C6)alkylamino, acetylamino(C1-C6)alkylamino, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylamino, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, (C6-C10)arylamino, (C6-C10)aryl(C1-C6)alkylamino, amino(C1-C6)alkylamino, (C2-C9)heterocycloalkylamino, (C2-C9)heteroarylamino, (C3-C10)cycloalkyl(C1-C6)alkyl)amino, (C1-C6)alkylcarbonylamino, (C1-C6)alkoxycarbonylamino, (C2-C6)alkenylcarbonylamino, (C3-C10)cycloalkylcarbonylamino, (C6-C10)arylcarbonylamino, (C2-C9)heterocycloalkylcarbonylamino, halo(C1-C6)alkylcarbonylamino, (C1-C6)alkoxy(C1-C6)alkylcarbonylamino, (C1-C6)alkoxycarbonyl(C1-C6)alkylcarbonylamino, ((C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino, ((C1-C6)alkoxycarbonyl)((C1-C6)alkyl)amino, (C1-C6)alkylsulfonylamino, (C3-C10)cycloalkylamino, ureido, (C1-C6)alkylureido, (C6-C10)arylureido, ((C6-C10)aryl)2ureido, (C6-C10)aryl(C1-C6)alkylureido, halo(C1-C6)alkylureido, ((C1-C6)alkyl)((C6-C10)aryl)ureido, ((C1-C6)alkyl)2ureido, halo(C1-C6)alkylcarbonylureido, glycinamido, (C1-C6)alkylglycinamido, aminocarbonylglycinamido, (C1-C6)alkoxy(C1-C6)alkylcarbonylglycinamido, (aminocarbonyl)((C1-C6)alkyl)glycinamido, ((C1-C6)alkoxycarbonyl(C1-C6)alkylcarbonyl)((C1-C6)alkyl)glycinamido, ((C1-C6)alkoxycarbonylamino(C1-C6)alkylcarbonyl)glycinamido, (C6-C10)arylcarbonylglycinamido, ((C6-C10)arylcarbonyl)((C1-C6)alkyl)glycinamido, ((C6-C10)aryl(C1-C6)alkylaminocarbonyl)glycinamido, (C6-C10)aryl(C1-C6)alkylaminocarbonyl)((C1-C6)alkyl)glycinamido, (C6-C10)arylaminocarbonylglycinamido and ((C6-C10)arylaminocarbonyl)((C1-C6)alkyl)glycinamido.
  • R[0077] 18 and R19 together with the nitrogen to which they are attached is selected from the group consisting of (C2-C9)heteroaryl(C1-C6)alkylamino, (C2-C9)heterocycloalkyl(C1-C6)alkylamino, (C1-C6)alkylsulfonylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkylamino, ureido(C1-C6)alkylamino, (C1-C6)alkylureido(C1-C6)alkylamino, ((C1-C6)alkyl)2ureido(C1-C6)alkylamino, halo(C1-C6)alkylamino, aminosulfonyl(C1-C6)alkylamino, (C1-C6)alkylaminosulfonyl(C1-C6)alkylamino, carboxy(C1-C6)alkylamino, (C1-C6)alkoxycarbonyl(C1-C6)alkylamino, cyano(C1-C6)alkylamino, aminocarbonyl(C1-C6)alkylamino, acetylamino(C1-C6)alkylamino, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylamino, (C1-C6)alkoxycarbonylamino(C1-C6)alkylamino, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylamino, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylamino, cyanoguanidino(C1-C6)alkylamino, (C1-C6)alkylcyanoguanidino(C1-C6)alkylamino, ((C1-C6)alkyl)2cyanoguanidino(C1-C6)alkylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkylamino, ureido(C1-C6)alkylamino, (C1-C6)alkylureido(C1-C6)alkylamino, ((C1-C6)alkyl)2ureido(C1-C6)alkylamino, aminocarbonyloxy(C1-C6)alkylamino, acetylamino(C1-C6)alkylcarbonylamino, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylcarbonylamino, aminocarbonyl(C1-C6)alkylcarbonylamino, (C1-C6)alkylaminocarbonyl(C1-C6)alkylcarbonylamino, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkylcarbonylamino, ureido(C1-C6)alkylcarbonylamino, (C1-C6)alkylureido(C1-C6)alkylcarbonylamino, ((C1-C6)alkyl)2ureido(C1-C6)alkylcarbonylamino, (C1-C6)alkoxycarbonylamino(C1-C6)alkylcarbonylamino, aminosulfonyl(C1-C6)alkylcarbonylamino, hydroxy(C1-C6)alkylamino(C1-C6)alkylcarbonylamino, (C1-C6)alkoxy(C1-C6)alkylamino(C1-C6)alkylcarbonylamino, (C2-C9)heterocycloalkyloxycarbonylamino, (C2-C9)heteroarylcarbonylamino(C1-C6)alkylcarbonylamino, (C2-C9)heterocycloalkylcarbonylamino(C1-C6)alkylcarbonylamino, cyanoguanidino(C1-C6)alkylcarbonylamino, cyano(C1-C6)alkylcarbonylamino, (C1-C6)alkylcarbonylamino(C1-C6)alkylamino-carbonylamino, amino(C1-C6)alkylaminocarbonylamino, (C1-C6)alkylamino(C1-C6)alkylaminocarbonyl amino, ((C1-C6)alkyl)2amino(C1-C6)alkylaminocarbonylamino carboxy(C1-C6)alkylaminocarbonyl amino, aminocarbonyl(C1-C6)alkylaminocarbonylamino, (C1-C6) alkylcarbonylamino(C1-C6)alkylaminocarbonylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkylaminocarbonylamino, (C1-C6)alkoxycarbonyl amino(C1-C6)alkylaminocarbonylamino, (C2-C9)heterocycloalkyloxycarbonyl amino(C1-C6)alkylaminocarbonylamino, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylaminocarbonylamino, (C2-C9)heterocycloalkyl(C1-C6)alkylaminocarbonylamino, (C2-C9)heteroaryl(C1-C6)alkylaminocarbonylamino, ureido(C1-C6)alkylureido, (C1-C6)alkylureido(C1-C6)alkylureido, ((C1-C6)alkyl)2ureido(C1-C6)alkylureido, cyanoguanidino(C1-C6)alkylureido, amino(C1-C6)alkylsulfonylamino, (C1-C6)alkylamino(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2amino(C1-C6)alkylsulfonylamino, acetylamino(C1-C6)alkylsulfonylamino, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylsulfonylamino, ureido(C1-C6)alkylsulfonylamino, (C1-C6)alkylureido(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2ureido(C1-C6)alkylsulfonylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkylsulfonylamino, cyanoguanidino(C1-C6)alkylsulfonylamino, (C1-C6)alkyl(cyanoguanidino)(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2(cyanoguanidino)(C1-C6)alkylsulfonylamino, aminocarbonyl(C1-C6)alkylsulfonylamino, (C1-C6)alkoxycarbonylamino(C1-C6)alkylsulfonylamino, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylsulfonylamino, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylsulfonylamino, aminosulfonylamino(C1-C6)alkyl, (C1-C6)alkylaminosulfonylamino, ((C1-C6)alkyl)2aminosulfonylamino(C1-C6)alkyl, cyanoguanidino, (C1-C6)alkyl(cyanoguanidino), ((C1-C6)alkyl)2(cyanoguanidino), (C2-C9)heterocycloalkyl(cyanoguanidino), (C2-C9)heterocycloalkyl(cyanoguanidino), (C2-C9)heteroaryl(cyanoguanidino), (C2-C9)heterocycloalkyl(C1-C6)alkyl(cyanoguanidino), (C2-C9)heteroaryl(C1-C6)alkyl(cyanoguanidino), amino(C1-C6)alkyl(cyanoguanidino), (C1-C6)alkylamino(C1-C6)alkyl(cyanoguanidino), ((C1-C6)alkyl)2amino(C1-C6)alkyl(cyanoguanidino), aminocarbonyl(C1-C6)alkyl(cyanoguanidino), (C1-C6)alkylaminocarbonyl(C1-C6)alkyl(cyanoguanidino), ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkyl(cyanoguanidino), (C2-C9)heterocycloalkyl, amino(C1-C6)alkylamino, (C1-C6)alkylamino(C1-C6)alkylamino, ((C1-C6)alkyl)2amino(C1-C6)alkylamino, (C2-C9)heteroarylamino, ureido(C1-C6)alkylamino, (C1-C6)alkylureido(C1-C6)alkylamino, ((C1-C6)alkyl)2ureido(C1-C6)alkylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkylamino, (C1-C6)alkoxycarbonylamino(C1-C6)alkylamino, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylamino, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylamino, aminocarbonyl(C1-C6)alkylamino, cyanoguanidino(C1-C6)alkylamino, (C2-C9)heteroaryl(C1-C6)alkylamino, (C2-C9)heterocycloalkylamino, (C1-C6)alkylcarbonylamino, halo(C1-C6)alkylcarbonylamino, (C1-C6)alkoxycarbonylamino, ureido, (C1-C6)alkylureido, ((C1-C6)alkyl)2ureido, amino, (C1-C6)alkylamino, (C3-C10)cycloalkylamino, ((C1-C6)alkyl)2amino, hydroxy(C1-C6)alkylamino, (C6-C10)arylamino, (C6-C10)aryl(C1-C6)alkylamino, (C1-C6)alkylcarbonylamino, (C6-C10)arylcarbonylamino, ((C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino, (C3-C10)cycloalkyl(C1-C6)alkyl)amino, (C1-C6)alkoxycarbonylamino, (C1-C6)alkoxycarbonyl(C1-C6)alkylcarbonylamino, ((C1-C6)alkoxycarbonyl)((C1-C6)alkyl)amino, (C1-C6)alkylsulfonylamino, ((C1-C6)alkylsulfonyl)((C1-C6)alkyl)amino, (C6-C10)arylsulfonylamino, ((C6-C10)arylsulfonyl)((C1-C6)alkyl)amino, (C2-C9)heterocycloalkylamino, (C2-C9)heteroarylamino, halo(C1-C6)alkylamino, (C6-C10)arylamino, (C6-C10)aryl(C1-C6)alkylamino, (aminocarbonyl(C1-C6)alkylamino, ((C1-C6)alkylaminocarbonyl(C1-C6)alkylamino, (carboxy(C1-C6)alkyl)amino, ((C1-C6)alkoxycarbonyl(C1-C6)alkylamino, (amino(C1-C6)alkyl)amino, (hydroxy(C1-C6)alkylamino, ureido, (C1-C6)alkylureido, ((C1-C6)alkyl)2ureido, (C6-C10)arylureido, (C6-C10)aryl)2ureido, (C6-C10)aryl(C1-C6)alkylureido, halo(C1-C6)alkylureido, (halo(C1-C6)alkyl)((C1-C6)alkyl)ureido, ((C1-C6)alkoxycarbonyl(C1-C6)alkyl)ureido, and glycinamido.
    Figure US20040058932A1-20040325-C00005
    Figure US20040058932A1-20040325-C00006
    Figure US20040058932A1-20040325-C00007
    Figure US20040058932A1-20040325-C00008
    Figure US20040058932A1-20040325-C00009
    Figure US20040058932A1-20040325-C00010
    Figure US20040058932A1-20040325-C00011
    Figure US20040058932A1-20040325-C00012
    Figure US20040058932A1-20040325-C00013
    Figure US20040058932A1-20040325-C00014
  • In reaction 1 of Preparation A, the compound of formula XXXV, wherein b is 0, 1 or 2, is converted to the corresponding compound of formula XXXIV by reacting XXXV with an ethyldiamine compound of the formula, (R[0078] 3)j-ethyldiamine, in the presence of an aprotic solvent, such as diethylether. The reaction mixture is heated to reflux for a time period between about 1 hour to about 12 hours.
  • In reaction 2 of Preparation A, the compound of formula XXXIV is converted to the corresponding compound of formula XXXIII by reducing XXXIV with a reducing agent, such as sodium borohydride, in a refluxing protic solvent, such as ethanol. In reaction 3 of Preparation A, the compound of formula XXXIII is converted to the corresponding compound of formula XXX by reacting XXXIII with a benzaldehyde compound of the formula [0079]
    Figure US20040058932A1-20040325-C00015
  • in the presence of a base, such as triethylamine, and a reducing agent, such as sodium triacetoxyborohydride, in an aprotic solvent, such as 1,2-dichloroethane. The reaction mixture is stirred at room temperature for a time period between about 1 hour to about 4 hours, preferably about 2 hours. [0080]
  • In reaction 1 of Preparation B, the compound of formula XXII, wherein b is 0, 1 or 2, is converted to the corresponding compound of formula XXI by reacting XXIII with a benzaldehyde compound of the formula [0081]
    Figure US20040058932A1-20040325-C00016
  • in the presence of a base, such as triethylamine, a reducing agent, such as sodium borohydride and an aprotic solvent, such as 1,2-dichloroethane. The reaction is stirred, at room temperature, for a time period between about 1 hour to about 4 hours, preferably about 2 hours. [0082]
  • In reaction 2 of Preparation B, the compound of formula XXI is converted to the corresponding compound of formula XX by first reacting a compound of the formula [0083]
    Figure US20040058932A1-20040325-C00017
  • wherein j is 0, 1 or 2, with 4-methyl morpholine and isobutylchloroformate in the presence of a polar aprotic solvent, such as tetrahydrofuran, followed by reacting the intermediate so formed with the compound of formula XXI. The reaction mixture, so formed, is stirred overnight at room temperature. [0084]
  • In reaction 3 of Preparation B, the compound of formula XX is converted to the corresponding piperizine-2,5-dione compound of formula XIX by treating XX with trifluoroacetic acid in the presence of a polar aprotic solvent, such as methylene chloride. The reaction is stirred, at room temperature, for a time period between about 1 hour to about 4 hours, preferably about 2 hours. [0085]
  • In reaction 4 of Preparation B, the compound of formula XIX is converted to the corresponding compound of formula XVIII by reducing XIX with a reducing agent, such as lithium aluminum hydride. The reaction is conducted at a temperature between about −10C to about 10C, preferably about 0° C., for a time period between about 10 minutes to about 90 minutes, preferably about 40 minutes. [0086]
  • In reaction 1 of the Preparation C, the compound of formula XXV is converted to the corresponding compound of formula XXIV by reacting XXV with an amine of the formula, NHR[0087] 18R19, wherein R18 and R19 are each independently selected from hydrogen, a nitrogen containing (C2-C9)heterocycloalkyl or (C2-C9)heteroaryl group, or (C1-C6)alkyl optionally substituted by hydroxy, aminocarbonyl, (C1-C6)alkylaminocarbonyl, ((C1-C6)alkyl)2carbonyl, carboxy, (C1-C6)alkylsulfonylamino, (C1-C6)alkoxycarbonylamino, aminosulfonyl, (C1-C6)alkylaminosulfonyl, ((C1-C6)alkyl)2aminosulfonyl, (C6-C10)alkoxy, (C2-C9)heteroaryl, (C2-C9)heterocycloalkyl, (C1-C6)alkylcarbonylamino, ((C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino, cyano, ureido, (C1-C6)alkylureido, ((C1-C6)alkyl)2ureido, cyanoguanidino, (C1-C6)alkylcyanoguanidino and ((C1-C6)alkyl)2cyanoguanidino, or R18 and R19 are taken together with the nitrogen to which they are attached to form a (C2-C9)heteroaryl or (C2-C9)heterocycloalkyl group, in the presence of a polar aprotic solvent, such as methylene chloride. The reaction mixture is stirred, at room temperature, for a time period between about 1 hour to about 24 hours, preferably about 12 hours.
  • In reaction 2 of Preparation C, the compound of formula XXIV is converted to the corresponding compound of formula XXIII by reacting XXIV with thiophenol in the presence of a base, such as sodium hydride, and a polar aprotic solvent, such as dimethylformamide. The reaction is heated to reflux for a time period between about 1 hour to about 10 hours, preferably about 4 hours. [0088]
  • In reaction 3 of Preparation C, the compound of formula XXV is converted to the corresponding compound of formula XXXVIII by reacting XXV with sodium cyanate in the presence of pyridine and a polar aprotic solvent, such as acetonitrile. The reaction is stirred, at room temperature, for a time period between about 2 hours to about 18 hours, preferably about 10 hours. An amine of the formula, H[0089] 2N—C(O)—NR18R19, is then added and the reaction mixture so formed is stirred, at room temperature, for a time period between about 2 hours to about 24 hours, preferably about 8 hours.
  • In reaction 4 of Preparation C, the compound of formula XXXVIII is converted to the corresponding compound of formula XXXVII according to the procedure described above in reaction 2 of Preparation C. [0090]
  • In reaction 1 of Scheme 1, the compound of formula XXX is converted to the corresponding compound of formula X by reacting XXX with a compound of the formula, A-(X)[0091] c—(Y)d-A, wherein A is chloro or bromo, in the presence of a base, such as triethylamine, and a polar aprotic solvent, such as methylene chloride. The reaction is stirred at a temperature between about −10° C. to about 10° C., for a time period between about 15 minutes to about 90 minutes, preferably about 30 minutes.
  • In reaction 2 of Scheme 1, the compound of formula X is converted to the corresponding compound of formula I by reacting X with a compound of the formula, H-(Z)[0092] e-R4 wherein e is 1 and Z is oxygen, in the presence of potassium carbonate, potassium iodide and an aprotic solvent, such as butanone. The reaction is heated to reflux for a time period between about 4 hours to about 8 hours, preferably about 6 hours.
  • In reaction 1 of Scheme 2, the compound of formula XXX is converted to the corresponding compound of formula I by reacting XXX with a compound of the formula, A-(X)[0093] c—(Y)d-(Z)e-R4, wherein A is chloro or bromo, in the presence of a base, such as triethylamine, and a polar aprotic solvent, such as methylene chloride. The reaction is stirred at a temperature between about −10° C. to about 10° C., for a time period between about 15 minutes to about 90 minutes, preferably about 30 minutes.
  • In reaction 1 of Scheme 3, the compound of formula X is converted to the corresponding compound of formula XII according to the procedure described above in reaction 2 of Scheme 1. [0094]
  • In reaction 2 of Scheme 3, the compound of formula XII is converted to the corresponding compound of formula XI by reacting XlI with lithium hydroxide monohydrate in the presence of methanol, tetrahydrofuran and water. The reaction mixture is stirred overnight at room temperature. [0095]
  • In reaction 3 of Scheme 3, the compound of formula XI is converted to the corresponding compound of formula II, by reacting Xl with an amine, in the presence of 4-dimethylaminopyridine, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimine and a polar aprotic solvent, such as methylene chloride. The resulting reaction mixture is stirred overnight at room temperature. [0096]
  • In reaction 1 of Scheme 4, the compound of formula X is converted to the corresponding compound of formula XV according to the procedure described above in reaction 2 of Scheme 1. [0097]
  • In reaction 2 of Scheme 4, the compound of formula XV is converted to the corresponding compound of formula XIV by hydrogenating XV in the presence of a catalyst, such as platinum on carbon, and a polar protic solvent, such as ethanol. The reaction is carried out under a pressure between about 30 psi to about 40 psi, preferably about 35 psi, for a time period between about 15 minutes to about 1 hour, preferably 30 minutes. [0098]
  • In reaction 3 of Scheme 4, for urea formation, the compound of formula XIV is converted to the corresponding compound of formula V by first reacting XIV with 4-nitrophenyl chloroformate in the presence of a base, such as pyridine, and a polar aprotic solvent, such as methlyene chloride, followed by reacting the intermediate so formed with an amine. The reaction mixture, so formed, is allowed to stir overnight at room temperature. For sulfonamide formation, the compound of formula XIV is reacted with a sulfonyl chloride compound of the formula, R[0099] 16—Cl, in the presence of a base, such as triethylamine, and a polar aprotic solvent, such as methylene chloride. The reaction is stirred overnight at ambient temperature. For cyanoguanidine formation, the compound of formula XIV is first treated with sodium hydride in an aprotic solvent, such as tetrahydrofuran, followed by reacting, the intermediate so formed with dimethyl-N-cyanodithio iminocarbonate. The reaction mixture so formed is heated to reflux overnight. The N-cyano-S-methyl-isothiourea intermediate is then reacted with an amine in the presence of a polar protic solvent, such as methanol. For amide formation, the compound of formula XIV is reacted with an acid, such as 3-tert-butoxycarbonylaminopropionic acid in the presence of N-methylmorpholine, O-benzotriazole-1-yl-N,N,N, N-tetramethyluronium hexafluorophosphate and a polar aprotic solvent, such as methylene chloride.
  • In reaction 1 of Scheme 5, the compound of formula X is converted to the corresponding compound of formula XVI, wherein k is 0, 1, 2, 3 or 4, according to the procedure described above in reaction 2 of Scheme 1. [0100]
  • In reaction 2 of Scheme 5, the compound of formula XVI is converted to the corresponding compound of formula VII by reacting XVI with an amine of the formula, R[0101] 16 R17N, wherein R16 and R17 are each indepenently hydrogen, a nitrogen containing (C2-C9)heterocycloalkyl or (C2-C9)heteroaryl group, or (C1-C6)alkyl optionally substituted by hydroxy, aminocarbonyl, (C1-C6)alkylaminocarbonyl, ((C1-C6)alkyl)2carbonyl, carboxy, (C1-C6)alkylsulfonylamino, (C1-C6)alkoxycarbonylamino, aminosulfonyl, (C1-C6)alkylaminosulfonyl,
  • ((C[0102] 1-C6)alkyl)2aminosulfonyl, (C6-C10)alkoxy, (C2-C9)heteroaryl, (C2-C9)heterocycloalkyl, (C1-C6)alkylcarbonylamino, ((C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino, cyano, ureido, (C1-C6)alkylureido, ((C1-C6)alkyl)2ureido, cyanoguanidino, (C1-C6)alkylcyanoguanidino and ((C1-C6)alkyl)2cyanoguanidino, in the presence of a 10:1 ratio solution of dichloroethane/acetic acid. The reaction mixture is stirred, at room temperature, for a time period between about 30 minutes to about 2 hours, preferably about 1 hour. A reducing agent, such as sodium cyanoborohydride is than added to the mixture and the reaction is allowed to stir overnight at room temperature. When R16 and/or R17 is/are hydrogen, the compound of formula VII may further be reacted according to the procedure described above in reaction 3 of Scheme 4, to provide ureas, sulfonamides, cyanoguanidinos, or amides.
  • In reaction 1 of Scheme 6, the compound of formula X is converted to the corresponding compound of formula XXXIX according to the procedure described above in reaction 2 of Scheme 1. [0103]
  • In reaction 2 of Scheme 6, the compound of formua X is converted to the corresponding compound of formula XXXX according to the procedure described above in reaction 2 of Scheme 1. [0104]
  • In reaction 1 of Scheme 7, the acid compound of formula XXXVI is converted to the corresponding compound of formula XXXII by treating XXXVI with thionyl chloride neat or in an aprotic solvent, at room temperature, for a time period between about 1 hour to about 24 hours, preferably 1 hour. The acid chloride so formed is dissolved in a polar aprotic solvent with a compound of the formula, (H[0105] 3CO)(H3C)NH.HCl, in the presence of an amine base, such as triethylamine. The reaction mixture is stirred, at room temperature, for a time period between about 1 hour to about 48 hours, preferably about 12 hours.
  • In reaction 2 of Scheme 7, the amide compound of formula XXXII is converted to the corresponding compound of formula XXXI by reacting XXXII with a (C[0106] 2-C9)heteroaryl lithium reagent in the presence of a polar aprotic solvent at a temperature between about −100° C. to room temperature, preferably about −78° C. The resulting reaction mixture is stirred for a time period between about 1 hour to about 24 hours, preferably about 12 hours, at a temperature between about −78° C. to about 50° C., preferably about 20° C.
  • Unless indicated otherwise, the pressure of each of the above reactions is not critical. Generally, the reactions will be conducted at a pressure of about one to about three atmospheres, preferably at ambient pressure (about one atmosphere). The compounds of the formula I which are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is obtained. [0107]
  • The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [1,1′-methylene-bis-(2-hydroxy-3-naphthoate)] salts. [0108]
  • Those compounds of the formula I which are also acidic in nature, are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the herein described acidic compounds of formula I. These non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium, calcium and magnesium, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum product yields. [0109]
  • Compounds of the formula I and their pharmaceutically acceptable salts (hereinafter also referred to, collectively, as “the active compounds”) are potent antagonists of the CCR1 receptors. The active compounds are useful in the treatment or prevention of autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult respiratory distress syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), chronic bronchitis, xeno-transplantation, transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases (including sarcoidosis, leprosy and tuberculosis). [0110]
  • The activity of the compounds of the invention can be assessed according to procedures know to those of ordinary skill in the art. Examples of recognized methods for determining CCR1 induced migration can be found in Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M., Strober, W. editors: [0111] Current Protocols In Immunology, 6.12.1-6.12.3. (John Wiley and Sons, NY, 1991). One specific example of how to determine the activity of a compound for inhibiting migration is described in detail below.
    • Chemotaxis Assay
  • The ability of compounds to inhibit the chemotaxis to various chemokines can be evaluated using standard 48 or 96 well Boyden Chambers with a 5 micron polycarbonate filter. All reagents and cells can be prepared in standard RPMI (BioWhitikker Inc.) tissue culture medium supplemented with 1 mg/ml of bovine serum albumin. Briefly, MIP-1 a (Peprotech, Inc., P.O. Box 275, Rocky Hill N.J.) or other test agonists, were placed into the lower chambers of the Boyden chamber. A polycarbonate filter was then applied and the upper chamber fastened. The amount of agonist chosen is that determined to give the maximal amount of chemotaxis in this system (e.g., 1 nM for MIP-1α should be adequate). [0112]
  • THP-1 cells (ATCC TIB-202), primary human monocytes, or primary lymphocytes, isolated by standard techniques can then be added to the upper chambers in triplicate together with various concentrations of the test compound. Compound dilutions can be prepared using standard serological techniques and are mixed with cells prior to adding to the chamber. [0113]
  • After a suitable incubation period at 37 degrees centigrade (e.g. 3.5 hours for THP-1 cells, 90 minutes for primary monocytes), the chamber is removed, the cells in the upper chamber aspirated, the upper part of the filter wiped and the number of cells migrating can be determined according to the following method. [0114]
  • For THP-1 cells, the chamber (a 96 well variety manufactured by Neuroprobe) can be centrifuged to push cells off the lower chamber and the number of cells can be quantitated against a standard curve by a color change of the dye fluorocein diacetate. [0115]
  • For primary human monocytes, or lymphocytes, the filter can be stained with Dif Quik® dye (American Scientific Products) and the number of cells migrating can be determined microscopically. [0116]
  • The number of cells migrating in the presence of the compound are divided by the number of cells migrating in control wells (without the compound). The quotant is the % inhibition for the compound which can then be plotted using standard graphics techniques against the concentration of compound used. The 50% inhibition point is then determined using a line fit analysis for all concentrations tested. The line fit for all data points must have an coefficient of correlation (R squared) of >90% to be considered a valid assay. [0117]
  • All of the compounds of the invention that were tested had IC[0118] 50 of less than 25 μM, in the Chemotaxis assay.
  • The compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers. Thus, the active compounds of the invention may be formulated for oral, buccal, intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or in a form suitable for administration by inhalation or insufflation. The active compounds of the invention may also be formulated for sustained delivery. [0119]
  • For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid). [0120]
  • For buccal administration, the composition may take the form of tablets or lozenges formulated in conventional manner. [0121]
  • The active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. [0122]
  • The active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides. [0123]
  • For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch. [0124]
  • A proposed dose of the active compounds of the invention for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above (e.g., rheumatoid arthritis) is 0.1 to 1000 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day. [0125]
  • Aerosol formulations for treatment of the conditions referred to above (eq., rheumatoid arthritis) in the average adult human are preferably arranged so that each metered dose or “puff” of aerosol contains 20 μg to 1000 μg of the compound of the invention. The overall daily dose with an aerosol will be within the range 0.1 mg to 1000 mg. Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each time. [0126]
  • The active agents can be formulated for sustained delivery according to methods well known to those of ordinary skill in the art. Examples of such formulations can be found in U.S. Pat. Nos. 3,538,214, 4,060,598, 4,173,626, 3,119,742, and 3,492,397. [0127]
  • The compounds of the invention can also be utilized in combination therapy with, but not limited to, other therapeutic agents such as with T-cell immunosuppressant agents such as rapamycin cyclosporin A and FK-506, with steroid sparing agents such as Cellcept®, or with classical anti-inflammatory agents (e.g. cyclooxygenase/lipoxygenase inhibitors) such as tenidap, aspirin, acetaminophen, naproxen and piroxicam. [0128]
  • The following Examples illustrate the preparation of the compounds of the present invention. NMR data are reported in parts per million (δ) and are referenced to the deuterium lock signal from the sample solvent (deuteriochloroform unless otherwise specified). Commercial reagents were utilized without further purification. THF refers to tetrahydrofuran. DMF refers to N,N-dimethylformamide. Chromatography refers to column chromatography performed using 32-63 mm silica gel and executed under nitrogen pressure (flash chromatography) conditions. Low Resolution Mass Spectra (LRMS) were recorded on either a Hewlett Packard 5989®, utilizing chemical ionization (ammonium), or a Fisons (or Micro Mass) Atmospheric Pressure Chemical Ionization (APCI) platform which uses a 50/50 mixture of acetonitrile/water with 0.1% formic acid as the ionizing agent. Room or ambient temperature refers to 20-25° C. All non-aqueous reactions were run under a nitrogen atmosphere for convenience and to maximize yields. The names for the compounds of the invention were created by the Autonom 2.0 PC-batch version from Beilstein Informationssysteme GmbH (ISBN 3-89536-976-4).[0129]
    • EXAMPLE 1
  • [0130]
    Figure US20040058932A1-20040325-C00018
    • (2R,5S)-2-[4-Chloro-2-(piperazine-1-carbonyl)-phenoxy]-1-[4-(4-fluoro-benzyl)-2.5-dimethyl-piperazin-1-yl]-ethanone
  • (R)-2-(4-Fluoro-benzylamino)-propionic Acid Methyl Ester [0131]
  • To a solution of (R)-2-amino-propionic acid methyl ester hydrochloride (25 g, 179 mmol) and 4-fluorobenzaldehyde (23 ml, 215 mmol) in 1,2-dichloroethane (200 ml) was added triethylamine (25 ml, 179 mmol). The resulting mixture was stirred for two hours at ambient temperature followed by addition of sodium acetoxyborohydride (57 g, 268 mmol) in four portions. The resulting mixture was stirred overnight at ambient temperature. The reaction was neutralized with dilute aqueous sodium hydroxide solution and extracted with dichloromethane (2×). The organic layers were combined, dried over magnesium sulfate, filtered and concentrated in vacuo. Chromatography on silica gel gave the title compound (34.4 g, 91% yield). [0132]
  • (2R,5S)-2-[(2-tert-Butoxycarbonylamino-propionyl)-(4-fluoro-benzyl)-amino]-propionic Acid Methyl Ester [0133]
  • To a solution of (R)-2-tert-butoxycarbonylamino-propionic acid (37 g, 195 mmol) in dry tetrahydrofuran (250 ml) at 0° C. was added 4-methyl morpholine (21.5 ml, 195 mmol) followed by isobutylchloroformate (25.3 ml, 195 mmol). The reaction was allowed to warm to ambient temperature and stirred for two hours. This was followed by the addition of (S)-2-(4-fluoro-benzylamino)-propionic acid methyl ester (34.4 g, 162 mmol). The resulting mixture was stirred overnight at ambient temperature. The reaction mixture was filtered through a pad of celite and the filter cake was washed with ethyl acetate. The filtrate was concentrated in vacuo, diluted with ethyl acetate and washed with water and brine. The organics were dried over magnesium sulfate, filtered and concentrated in vacuo. Chromatography on silica gel gave the title compound (43.2 g, 70% yield). [0134]
  • (2R,5S)-1-(4-Fluoro-benzyl)-3.6-dimethyl-piperazine-2,5-dione [0135]
  • To a solution of (2R,5S)-2-[(2-tert-butoxycarbonylamino-propionyl)-(4-fluorobenzyl)-amino]-propionic acid methyl ester (43 g, 382 mmol) in dichloromethane (120 ml) at 0° C. was added trifluoroacetic acid (60 ml). The reaction was allowed to warm to ambient temperature and stirred for 2 hours. The reaction was cooled to 0° C. and slowly quenched by addition of 3N aqueous sodium hydroxide until basic. The resulting mixture was extracted with dichloromethane (2×). The combined organics were dried over magnesium sulfate, filtered and concentrated in vacuo to give the title compound (22 g, 78% yield). [0136]
  • (2R, 5S)-1-(4-Fluoro-benzyl)-2,5-dimethyl-piperazine [0137]
  • To a solution of (2R, 5S)-1-(4-fluoro-benzyl)-3,6-dimethyl-piperazine-2,5-dione (22 g, 87.9 mmol) in dry tetrahydrofuran (160 ml) at 0° C. was added a solution of lithium aluminum hydride (1 M in tetrahydrofuran, 373 ml, 373 mmol) dropwise over 40 minutes. The reaction mixture was then refluxed for 4 hours, cooled to ambient temperature and slowly quenched with water. The resulting mixture was filtered through a pad of celite and the filter cake was washed with ethyl acetate. The filtrate was then concentrated, diluted with ethyl acetate and washed with saturated aqueous sodium hydrogen carbonate. The organic layer was separated, dried over magnesium sulfate, filtered and concentrated in vacuo to give the title compound (17.7 g, 91% yield). [0138]
  • (2R, 5S)-2-Chloro-1-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-ethanone [0139]
  • To a solution of (2R, 5S)-1-(4-fluoro-benzyl)-2,5-dimethyl-piperazine (2.5 g, 11.25 mmol) in dry dichloromethane (11 ml) at 0° C. was added triethylamine (1.57 ml, 11.2 mmol) followed by chloroacetyl chloride (0.858 ml, 11.2 mmol). The resulting reaction mixture was stirred for 30 minutes. The reaction was then filtered through a pad of celite, washed with dichloromethane and the resulting filtrate was concentrated to give a yellow oil. Chromatography on silica get gave the title compound (2.84 g, 86% yield). [0140]
  • (2R. 5S)-5-Chloro-2-[2-[4-(4-fluoro-benzyl)-2.5-dimethyl-pilerazin-1-yl]-2-oxo-ethoxy]-benzoic Acid Methyl Ester [0141]
  • To a solution of (2R, 5S)-2-chloro-1-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-ethanone (2.75 g, 9.2 mmol) in butanone (50 ml) was added methyl 5-chloro-2-hydroxybenzoate (1.55 g, 9.2 mmol), potassium carbonate (2.54 g, 18.4 mmol) and potassium iodide (1.52 g, 9.2 mmol). The resulting mixture was stirred at reflux for 6 hours. The reaction was then cooled, diluted with ethyl acetate, and washed with brine. The organics were dried over magnesium sulfate, filtered and concentrated in vacuo to give an orange oil. Chromatography on silica gel gave the title compound (4.1 g, 100% yield). [0142]
  • (2R, 5S)-5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzoic Acid [0143]
  • To a solution of (2R, 5S)-5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzoic acid methyl ester (4.12 g, 9.18 mmol) in tetrahydrofuran (10 ml), methanol (10 ml) and water (4 ml) was added lithium hydroxide monohydrate (1.93 g, 45.9 mmol). The resulting mixture was stirred overnight at ambient temperature. The reaction was then concentrated, diluted with 1N hydrochloric acid and extracted with dichloromethane (2×). The organic layers were combined, dried over magnesium sulfate, filtered and concentrated to give a white foam. Triteration in dichloromethane and diethyl ether gave the title compound (1.38 g, 35% yield). [0144]
  • (2R, 5S)-4-(5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzoyl)-piperazine-1-carboxylic Acid Tert-Butyl Ester [0145]
  • To a solution of (2R, 5S)-5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzoic acid (0.10 g, 0.212 mmol) in dichloromethane (4 ml) was added 4-dimethylaminopyridine (0.039 g, 0.318 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.061 g, 0.318 mmol) and tert-butyl 1-piperazinecarboxylate (0.041 g, 0.222 mmol). The resulting mixture was stirred overnight at ambient temperature. It was then diluted with dichloromethane and washed with brine. The organics were dried over magnesium sulfate, filtered and concentrated to give a clear oil. Chromatography on silica gel gave the title compound (0.110 g, 85% yield). [0146]
  • (2R, 5S)-2-[4-Chloro-2-(piperazine-1-carbonyl)-phenoxy]-1-[4-(4-fluoro-benzyl)-2.5-dimethyl-piperazin-1-yl]-ethanone [0147]
  • To a solution of (2R, 5S)[0148] 4-(5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzoyl)-piperazine-1-carboxylic acid tert-butyl ester (0.110 g, 0.182 mmol) in dichloroethane (10 ml) wass added trifluoroacetic acid (5 ml). The reaction was stirred for two hours at ambient temperature. The reaction was then diluted with dichloromethane and washed with 1 N aqueous sodium hydroxide. The organics were dried over magnesium sulfate, filtered and concentrated to give the title compound (0.080 g, 87% yield).
  • The title compounds for Examples 2-12 were prepared by a method analogous to that described in Example 1. [0149]
    Figure US20040058932A1-20040325-C00019
    Example R20 R2
    2
    Figure US20040058932A1-20040325-C00020
         		Me
    3
    Figure US20040058932A1-20040325-C00021
         		Me
    4
    Figure US20040058932A1-20040325-C00022
         		H
    5
    Figure US20040058932A1-20040325-C00023
         		H
    6
    Figure US20040058932A1-20040325-C00024
         		H
    7
    Figure US20040058932A1-20040325-C00025
         		H
    8
    Figure US20040058932A1-20040325-C00026
         		H
    9
    Figure US20040058932A1-20040325-C00027
         		H
    10 —NHSO2Me Me
    11 —NH—(CH2)2—NHSO2CH3 CH3
    12 —NH—(CH2)2—NHC(O)NH2 CH3
    • EXAMPLE 13
  • [0150]
    Figure US20040058932A1-20040325-C00028
    • (2R)-3-Amino-N-(5-chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-propionamide
  • [2-(5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo-ethoxy}-phenylcarbanoyl)-ethyl]-carbamic Acid Tert-Butyl Ester [0151]
  • To a solution of 2-(2-amino-4-chloro-phenoxy)-1-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-ethanone (0.066 g, 0.17 mmol) in methylene chloride (2 mL) at ambient temperature was added N-methylmorpholine (0.025 mL, 0.23 mmol), 3-tert-butoxycarbonylamino-propionic acid (0.044 g, 0.23 mmol) and O-benzotriazole-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate (0.076 g, 0.20 mmol). The resulting solution was stirred at ambient temperature for 60 hours, then concentrated. Radial chromatography (2 mm plate) gave the title compound (0.114 g) [0152]
  • (2R)-3-Amino-N-(5-chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-propionamide [0153]
  • To a solution of [2-(5-chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo-ethoxy}-phenylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester (0.110 g, 0.2 mmol) in methylene chloride (3 mL) was added trifluoroacetic acid (0.50 mL). The reaction was stirred for 2 hours at ambient temperature then diluted with saturated aqueous sodium hydrogen carbonate. The mixture was extracted with methylene chloride and the combined organics were dried over magnesium sulfate, filtered and concentrated in vacuo to give the title compound (0.069 g) [0154]
  • The title compounds for Examples 14-19 were prepared by a method analogous to that described in Example 13. [0155]
    Figure US20040058932A1-20040325-C00029
    Example R20 R2
    14
    Figure US20040058932A1-20040325-C00030
         		H
    15
    Figure US20040058932A1-20040325-C00031
         		H
    16
    Figure US20040058932A1-20040325-C00032
         		H
    17
    Figure US20040058932A1-20040325-C00033
         		H
    18
    Figure US20040058932A1-20040325-C00034
         		H
    19
    Figure US20040058932A1-20040325-C00035
         		H
    • EXAMPLE 20
  • [0156]
    Figure US20040058932A1-20040325-C00036
  • (2R,5S)-1-(2-Amino-ethyl)-3-(5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy)-phenyl)-urea [0157]
  • (2R, 5S)-2-(4-Chloro-2-nitro-phenoxy)-1-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-ethanone [0158]
  • To a solution of (2R, 5S)-5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzoic acid methyl ester (1.0 g, 3.35 mmol) in butanone (35 ml) was added 2-nitro-4-chlorophenol (0.639 g, 3.69 mmol), potassium carbonate (0.925 g, 6.7 mmol) and potassium iodide (0.556 g, 3.35 mmol). The reaction mixture was heated at reflux overnight. The reaction mixture was then cooled, diluted with water and extracted with ethyl acetate. The combined organics were dried over magnesium sulfate, filtered and concentrated to give an orange oil. Chromatography on silica gel gave the title compound (1.35 g, 93% yield). [0159]
  • (2R, 5S)-2-(2-Amino-4-chloro-phenoxy)-1-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-ethanone [0160]
  • To a solution of (2R, 5S)-2-(4-chloro-2-nitro-phenoxy)-1-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-ethanone (2.2 g, 5.05 mmol) in ethanol (50 ml) in a par bottle was added 5% platinum on carbon (2.2 g). The reaction mixture was subjected to hydrogen gas (35 psi) for thirty minutes. The reaction mixture was filtered through celite and washed with ethanol. The filtrate was concentrated to give a tan foam. Chromatography on silica gel gave the title compound (1.42 g, 70% yield). [0161]
  • (2R, 5S)-(5-Chloro-2-[2-[4-(4-fluoro-benzyl)-2.5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-carbamic acid 4-nitro-phenyl Ester [0162]
  • To a solution of (2R, 5S)-2-(2-amino-4-chloro-phenoxy)-1-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-ethanone (0.150 g, 0.37 mmol) in dichloromethane (7 ml) was added pyridine (0.066 ml, 0.82 mmol) followed by 4-nitrophenyl chloroformate (0.075 g, 0.41 mmol). The reaction was stirred at ambient temperature for 3 ½ hours. The reaction mixture was concentrated followed by chromatography on silica gel to give the title compound (0.153 g, 74% yield). [0163]
  • (2R,5S)-1-(2-Amino-ethyl)-3-(5-chloro-2-[2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy]-phenyl)-urea [0164]
  • To a solution of (2R, 5S)-(5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-carbamic acid 4-nitro-phenyl ester (0.206 g, 0.37 mmol) in dry methanol (6 ml) was added ethyldiamine (0.05 ml, 0.814 mmol). The reaction was stirred at ambient temperature overnight. The reaction was concentrated and chromatagraphed on silica gel to give the title compound (0.115 g, 63% yield). [0165]
  • The title compounds for Examples 21-27 were prepared by a method analogous to that described in Example 20. [0166]
    Figure US20040058932A1-20040325-C00037
    Example R20 R2
    21
    Figure US20040058932A1-20040325-C00038
         		Me
    22
    Figure US20040058932A1-20040325-C00039
         		H
    23
    Figure US20040058932A1-20040325-C00040
         		Me
    24
    Figure US20040058932A1-20040325-C00041
         		H
    25
    Figure US20040058932A1-20040325-C00042
         		H
    26
    Figure US20040058932A1-20040325-C00043
         		H
    27
    Figure US20040058932A1-20040325-C00044
         		Me
    • EXAMPLE 28
  • [0167]
    Figure US20040058932A1-20040325-C00045
    • (2R)-2-Amino-ethanesulfonic acid (5-chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-amide
  • 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethanesulfonic acid (5-chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-amide [0168]
  • To a solution of of 2-(2-amino-4-chloro-phenoxy)-1-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-ethanone (0.050 g, 0.13 mmol) in methylene chloride (1 mL) at ambient temperature was added triethylamine (0.027 mL, 0.19 mmol) and 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethanesulfonyl chloride (0.045 g, 0.17 mmol). The reaction was stirred overnight at ambient temperature. Additional triethylamine ((0.027 mL, 0.19 mmol) and 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethanesulfonyl chloride (0.045 g, 0.17 mmol) was added. The reaction was stirred one hour, then additional triethylamine (0.055 mL, 0.34 mmol) was added. The reaction was stirred and hour, then additional 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethanesulfonyl chloride (0.090 g, 0.34 mmol) was added. After stirring an additional 1 hour, the reaction was treated with saturated aqueous sodium hydrogen carbonate and extracted with methylene chloride (3×). The combined organics were dried over magnesium sulfate, filtered and concentrated in vacuo. Purification via radial chromatography (2 mm plate) gave the title compound (0.030 g). [0169]
  • (2R)-2-Amino-ethanesulfonic acid (5-chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-amide [0170]
  • To a solution of 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethanesulfonic acid (5-chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-amide (0.030 g, 0.048 mmol) in EtOH (1 mL) at ambient temperature was added hydrazine hydrate (0.025 mL). The reaction was stirred overnight at ambient temperature then diluted with water and extracted with methylene chloride (2×). The combined organics were washed with saturated aqueous brine and dried over sodium sulfate, filtered and concentrated in vacuo. Purification via radial chromatography (2 mm plate) gave the title compound (0.014 g). [0171]
  • The title compounds for Examples 29-34 were prepared by a method analogous to that described in Example 28. [0172]
    Figure US20040058932A1-20040325-C00046
    Example R20 R2
    29 —SO2CF3 Me
    30
    Figure US20040058932A1-20040325-C00047
         		H
    31
    Figure US20040058932A1-20040325-C00048
         		H
    32
    Figure US20040058932A1-20040325-C00049
         		H
    33
    Figure US20040058932A1-20040325-C00050
         		H
    34 —SO2N(Me)2 Me
    • EXAMPLE 35
  • [0173]
    Figure US20040058932A1-20040325-C00051
    • (2R)-N-(5-Chloro-242-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo-ethoxy]-phenyl)-cyanoguanidine
  • 1-(5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-N-cyano-S-methyl-isothiourea [0174]
  • To a solution of of 2-(2-amino-4-chloro-phenoxy)-1-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-ethanone (0.30 g, 0.77 mmol) in tetrahydrofuran (5 mL) at ambient temperature was added sodium hydride (0.029 g, 1.22 mmol) and the reaction was stirred for 30 minutes. To this was added S,S1-dimethyl N-cyanodithio iminocarbonate (0.168, 1.15 mmol) and the mixture was heated at reflux overnight. The reaction was cooled and quenched with saturated aqueous ammonium chloride. The mixture was extracted with EtOAc and the combined organics were dried over Na[0175] 2SO4, filtered and concentrated in vacuo. Chromatography on silica gel gave the title compound (0.350 g)
  • (2R)-N-(5-Chloro-2-[2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo-ethoxy]-phenyl)-cyanoguanidine [0176]
  • To a solution of 1-(5-chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-N-cyano-S-methyl-isothiourea (0.045 g, 0.092 mmol) in EtOH (1 mL) was added ammonium hydroxide (0.100 mL) and the resulting solution was shaken at 60° C. overnight. The crude reaction mixture was purified directly via radial chromatography (2 mm plate) to give the title compound (0.027 g). The title compounds for Examples 36-38 were prepared by a method analogous to that described in Example 35. [0177]
    Figure US20040058932A1-20040325-C00052
    Figure US20040058932A1-20040325-C00053
    Example R20 R2
    36
    Figure US20040058932A1-20040325-C00054
         		H
    37
    Figure US20040058932A1-20040325-C00055
         		H
    38
    Figure US20040058932A1-20040325-C00056
         		H
    • EXAMPLE 39
  • [0178]
    Figure US20040058932A1-20040325-C00057
    • (2R,5S)-2-{4-Chloro-2-[(2-diethylaminothylamino)-methyl]-phenoxy}-1-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-ethanone
  • (2R,5S)-5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2.5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzaldehyde [0179]
  • To a solution of 2-chloro-1-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-ethanone (2.87 g, 9.6 mmol) in DMF (20 mL) was added 5-chlorosalicylaldehyde (1.65 g, 10.5 mmol), potassium carbonate (2.64 g, 19.2 mmol) and potassium iodide (1.59 g, 9.6 mmol). The resulting mixture was heated to 100° C. for 12 hours. The reaction was cooled, diluted with saturated aqueous brine and extracted with ethyl acetate (3×). The combined organics were dried over magnesium sulfate and filtered. The filtrate was concentrated in vacuo to give crude product. Purification via chromatography on silica gel (15% EtOAc/Hexanes) gave the title compound 3.40 g, 85% yield.) [0180]
  • (2R,5S)-2-{4-Chloro-2-[(2-diethylamino-ethylamino)-methyl]-phenoxy}-1-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-ethanone [0181]
  • To a solution of (2R,5S)-5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzaldehyde (0.100 g, 0.25 mmol) in 10:1 dichloroethane acetic acid (2.2 mL) was added (diethylamino)ethylamine (0.088 mL, 0.625 mmol) and the resulting solution was stirred for 1 hour at ambient temperature. To this was added sodium cyanoborohydride (0.0094 g, 0.15 mmol) and the reaction was stirred overnight at ambient temperature. Upon completion water was added and the mixture was basified with solid sodium bicarbonate (pH>10). The product was extracted with dichloromethane (2×) and diethyl ether (2×). The combined organics were dried over magnesium sulfate, filtered and concentrated in vacuo. Chromatography on silica gel gave the title compound (0.039 g,×30% yield) [0182]
  • The title compounds for Examples 40-62 were prepared by a method analogous to that described in Example 39. [0183]
    Figure US20040058932A1-20040325-C00058
    Example R20 R2
    40
    Figure US20040058932A1-20040325-C00059
         		Me
    41
    Figure US20040058932A1-20040325-C00060
         		Me
    42
    Figure US20040058932A1-20040325-C00061
         		Me
    43
    Figure US20040058932A1-20040325-C00062
         		Me
    44
    Figure US20040058932A1-20040325-C00063
         		Me
    45
    Figure US20040058932A1-20040325-C00064
         		Me
    46
    Figure US20040058932A1-20040325-C00065
         		Me
    47
    Figure US20040058932A1-20040325-C00066
         		Me
    48
    Figure US20040058932A1-20040325-C00067
         		Me
    49
    Figure US20040058932A1-20040325-C00068
         		Me
    50
    Figure US20040058932A1-20040325-C00069
         		Me
    51
    Figure US20040058932A1-20040325-C00070
         		Me
    52
    Figure US20040058932A1-20040325-C00071
         		Me
    53
    Figure US20040058932A1-20040325-C00072
         		Me
    54
    Figure US20040058932A1-20040325-C00073
         		Me
    55
    Figure US20040058932A1-20040325-C00074
         		Me
    56
    Figure US20040058932A1-20040325-C00075
         		Me
    57
    Figure US20040058932A1-20040325-C00076
         		Me
    58
    Figure US20040058932A1-20040325-C00077
         		Me
    59
    Figure US20040058932A1-20040325-C00078
         		Me
    60
    Figure US20040058932A1-20040325-C00079
         		Me
    61
    Figure US20040058932A1-20040325-C00080
         		Me
    62
    Figure US20040058932A1-20040325-C00081
         		Me
    • EXAMPLE 63
  • [0184]
    Figure US20040058932A1-20040325-C00082
    • N-(5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzyl)-2-diethylamino-acetamide
  • (2R,5S)-2-(2-Aminomethyl-4-chloro-phenoxy)-1-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-ethanone [0185]
  • To a solution of (2R,5S)-5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzaldehyde (1.86 g, 4.44 mmol) in MeOH (20 mL) was added ammonium acetate (3.42 g, 44 mmol) and sodium cyanoborohydride (0.195 g, 3.1 mmol). The resulting mixture was stirred overnight at ambient temperature. The reaction was quenched with concentrated hydrochloric acid and concentrated in vacuo. The residue was dissolved in water and basified with aqueous 3N NaOH (pH>10). The product was extracted with dichloromethane (2×) and ethyl acetate (2×). The combined organics were dried over magnesium sulfate, filtered and concentrated in vacuo. Chromatography on silica gel gave the title compound (1.29 g, 69% yield) [0186]
  • N-(5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2.5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzyl)-2-diethylamino-acetamide [0187]
  • To a solution of N,N-dimethylglycine (0.014 g, 0.13 mmol) and (2R,5S)-2-(2-aminomethyl-4-chloro-phenoxy)-1-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-ethanone (0.063 g, 0.15 mmol) in dichloromethane (2 mL) was added 1-(3-dimethlaminopropyl)-3-ethylcarbodiimide (0.034 g, 0.18 mmol), 1-hydroxybenzotriazole (0.021 g, 0.15 mmol), and triethylamine (0.036 mL, 0.36 mmol). After the reaction was stirred for 48 hours, the solution was diluted with saturated aqueous sodium bicarbonate and extracted with dichloromethane (3×). The combined organics were dried over magnesium sulfate, filtered and concentrated in vacuo. Chromatography on silica gel gave the title compound (0.063 g, 80%). [0188]
  • The title compounds for Examples 64-85 were prepared by a method analogous to that described in Example 63. [0189]
    Figure US20040058932A1-20040325-C00083
    Example R20 R2
    64
    Figure US20040058932A1-20040325-C00084
         		Me
    65
    Figure US20040058932A1-20040325-C00085
         		Me
    66
    Figure US20040058932A1-20040325-C00086
         		Me
    67
    Figure US20040058932A1-20040325-C00087
         		Me
    68
    Figure US20040058932A1-20040325-C00088
         		Me
    69
    Figure US20040058932A1-20040325-C00089
         		Me
    70
    Figure US20040058932A1-20040325-C00090
         		Me
    71
    Figure US20040058932A1-20040325-C00091
         		Me
    72
    Figure US20040058932A1-20040325-C00092
         		Me
    73
    Figure US20040058932A1-20040325-C00093
         		Me
    74
    Figure US20040058932A1-20040325-C00094
         		Me
    75
    Figure US20040058932A1-20040325-C00095
         		Me
    76
    Figure US20040058932A1-20040325-C00096
         		Me
    77
    Figure US20040058932A1-20040325-C00097
         		Me
    78
    Figure US20040058932A1-20040325-C00098
         		H
    79
    Figure US20040058932A1-20040325-C00099
         		H
    80
    Figure US20040058932A1-20040325-C00100
         		Me
    81
    Figure US20040058932A1-20040325-C00101
         		Me
    82
    Figure US20040058932A1-20040325-C00102
         		Me
    83
    Figure US20040058932A1-20040325-C00103
         		Me
    84
    Figure US20040058932A1-20040325-C00104
         		H
    85
    Figure US20040058932A1-20040325-C00105
         		H
    • EXAMPLE 86
  • [0190]
    Figure US20040058932A1-20040325-C00106
    • (2R,5S)-(N-{2-[3-(5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzyl)-ureido]-ethyl}-acetamide
  • To a solution of (2R,5S)-5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzylamine (0.200 g, 0.477 mmol) in methylene chloride (10 mL) was added pyridine(0.077 mL, 0.954 mmol) and 4-nitro phenyl chloroformate (0.097 g, 0.525 mmol). The resulting mixture was stirred for one hour at ambient temperature and then concentrated in vacuo. The residue (0.055 g, 0.094 mmol) was dissolved in methanol (1 mL). N-Acetylethylenediamine (0.019 mL, 0.188 mmol) was added and the reaction was stirred at room temperature over night. The reaction was concentrated in vacuo and chromatography on silica gel gave the title compound (0.019 g, 27%). [0191]
  • The title compounds for Examples 87-90 were prepared by a method analogous to that described in Example 86. [0192]
    Figure US20040058932A1-20040325-C00107
    Example R20 R2
    87
    Figure US20040058932A1-20040325-C00108
         		Me
    88
    Figure US20040058932A1-20040325-C00109
         		Me
    89
    Figure US20040058932A1-20040325-C00110
         		Me
    90
    Figure US20040058932A1-20040325-C00111
         		Me
    • EXAMPLE 91
  • [0193]
    Figure US20040058932A1-20040325-C00112
    • (2R,5S)-2-Amino-ethanesulfonic Acid 5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzylamide
  • (2R,5S)-2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethanesulfonic acid 5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzylamide [0194]
  • To a solution of (2R,5S)-5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzyl amine (0.060 g, 0.143 mmol) in methylene chloride (3 ml) was added 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethanesulfonyl chloride (0.043 g, 0.150 mmol) and triethylamine (0.060 mL, 0.43 mmol) and the solution was stirred 1 hr at ambient temperature. The reaction was diluted with saturated aqueous sodium hydrogen carbonate and extracted with methylene chloride. The combined organics were dried over magnesium sulfate, filtered and concentrated in vacuo. Chromatography on silica gel gave the title compound (0.073 g, 77%). [0195]
  • (2R,5S)-2-Amino-ethanesulfonic acid 5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzylamide [0196]
  • To a solution of (2R,5S)-2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethanesulfonic acid 5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzylamide (0.073 g, 0.111 mmol) in EtOH (1 mL) was added hydrazine (35% aq. 0.25 mL, 2.73 mmol) and the solution was stirred overnight at ambient temperature. The reaction was filtered through a glass frit and washed with EtOH. The filtrate was concentrated in vacuo to give the title compound (0.056 g, 96%) [0197]
  • The title compounds for Examples 92-93 were prepared by a method analogous to that described in Example 91. [0198]
    Figure US20040058932A1-20040325-C00113
    Example R20 R2
    92
    Figure US20040058932A1-20040325-C00114
         		H
    93 —SO2NMe2 Me
    • EXAMPLE 94
  • [0199]
    Figure US20040058932A1-20040325-C00115
  • (2R)-N-(2-Amino-ethyl)-N′-(5-chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo-ethoxy}-benzyl)-cyanoguanidine [0200]
  • A solution of 2-(2-aminomethyl-4-chloro-phenoxy)-1-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-ethanone (0.025 g, 0.062 mmol) and diphenyl cyanocarbonimidate (0.016 g, 0.068 mmol) in ethanol (1 mL) was heated on a shaker plate at 60° C. After 22 h, ethylenediamine (0.008 mL, 0.123 mmol) was added and the resulting solution was heated on a shaker plate at 60° C. for an additional 21 h. The solution was cooled to ambient temperature, concentrated and purified using radial chromatography to yield the title compound (0.021 g, 67%). The title compounds for Examples 95-96 were prepared by a method analogous to that described in Example 94. [0201]
    Figure US20040058932A1-20040325-C00116
    Example R20 R2
    95
    Figure US20040058932A1-20040325-C00117
         		H
    96
    Figure US20040058932A1-20040325-C00118
         		H
    • EXAMPLE 97
  • [0202]
    Figure US20040058932A1-20040325-C00119
    • (2R, 5S)-5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-N-methyl-benzenesulfonamide
  • 5-Chloro-2-methoxy-N-methyl-benzenesulfonamide [0203]
  • To a solution of 5-Chloro-2-methoxy-benzenesulfonyl chloride (1.0 g, 4.15 mmol) in tetrahydrofuran(8 ml) was bubbled methylamine gas until saturated. The reaction mixture was sealed with a septa and stirred overnight at ambient temperature. The reaction mixture was then concentrated, triterated in dichloromethane and ether, filtered and dried yielding the above titled compound 1.05 g (>100%) white solid. [0204]
  • 5-Chloro-2-hydroxy-N-methyl-benzenesulfonamide [0205]
  • To a solution of sodium hydride (60% in mineral oil, 90.24 mg, 2.25 mmol) in dry dimethyl formamide was added thiophenol (0.225 ml, 2.25 mmol) dropwise. To this was then added 5-Chloro-2-methoxy-N-methyl-benzenesulfonamide (531 mg, 2.25 mmol) followed by refluxing for 4 hours. The reaction mixture was cooled, diluted with ethyl acetate and washed with a 1N sulfuric acid solution. The organic layer was separated, dried over magnesium sulfate, filtered and concentrated in vacuo. Chromatography on silica gel yielded the above titled compound (320 mg, 53% yield). [0206]
  • (2R, 5S)-5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-N-methyl-benzenesulfonamide [0207]
  • To a solution of (2R, 5S)-2-Chloro-1-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-ethanone (375 mg, 1.26 mmol) in butanone (12 ml) was added 5-Chloro-2-hydroxy-N-methyl-benzenesulfonamide (280 mg, 1.26 mmol), potassium carbonate (348 mg, 2.52 mmol) and potassium iodide (209 mg, 1.26 mmol). The resulting reaction mixture was refluxed for 4 hours. It was allowed to cool, diluted with ethyl acetate and washed with brine. The organic layer was separated, dried over magnesium sulfate, filtered and concentrated in vacuo. Chromatography on silica gel gave the above titled compound (320 mg, 53% yield). [0208]
  • The title compounds for Examples 98-100 were prepared by a method analogous to that described in Example 97. [0209]
    Figure US20040058932A1-20040325-C00120
    Example R20 R2
     98 —NH2 Me
     99
    Figure US20040058932A1-20040325-C00121
         		Me
    100
    Figure US20040058932A1-20040325-C00122
         		Me

Claims (13)

1. A compound of the formula
Figure US20040058932A1-20040325-C00123
or the pharmaceutically acceptable salt thereof; wherein
a is 1, 2, 3, 4 or 5;
b is 0, 1, 2, 3 or 4;
c is 0 or 1;
d is 1, 2, 3, 4 or 5;
e is 0 or 1;
j is 1, 2, 3, or 4;
X is C(O), C(S) or CH2;
Y is CH2, or if e is 0, Y is CHR8 wherein R8 is hydrogen, (C6-C10)aryl or NR9R10;
Z is oxygen, NR9 or CR11R12;
each R1 is independently selected from hydrogen, hydroxy, hydroxysulfonyl, halo, (C1-C6)alkyl, mercapto, mercapto(C1-C6)alkyl, (C1-C6)alkylthio, (C1-C6)alkylsulfinyl, (C1-C6)alkylsufonyl, (C1-C6)alkylthio(C1-C6)alkyl, (C1-C6)alkylsulfinyl(C1-C6)alkyl, (C1-C6)alkylsulfonyl(C1-C6)alkyl, (C1-C6)alkoxy, (C6-C10)aryloxy, halo(C1-C6)alkyl, trifluoromethyl, formyl, formyl(C1-C6)alkyl, nitro, nitroso, cyano, (C6-C10)aryl(C1-C6)alkoxy, halo(C1-C6)alkoxy, trifluoromethoxy, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, hydroxy(C3-C7)cycloalkyl(C1-C6)alkyl, (C3-C7)cycloalkylamino, (C3-C7)cycloalkylamino(C1-C6)alkyl, ((C3-C7)cycloalkyl)((C1-C6)alkyl)amino, ((C3-C7)cycloalkyl(C1-C6)alkyl)amino(C1-C6)alkyl, cyano(C1-C6)alkyl, (C2-C7)alkenyl, (C2-C7)alkynyl, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl, (C6-C10)aryl(C2-C6)alkenyl, hydroxy(C1-C6)alkyl, hydroxy(C6-C10)aryl(C1-C6)alkyl, hydroxy(C1-C6)alkylthio(C1-C6)alkyl, hydroxy(C2-C6)alkenyl, hydroxy(C2-C6)alkynyl, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxy(C6-C10)aryl(C1-C6)alkyl, (C6-C10)aryloxy(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkoxy(C1-C6)alkyl, amino, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, (C6-C10)arylamino, (C6-C10)aryl(C1-C6)alkylamino, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkyl, hydroxy(C1-C6)alkylamino(C1-C6)alkyl, (C6-C10)arylamino(C1-C6)alkyl, (C6-C10)aryl (C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkylcarbonylamino, ((C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino, (C1-C6)alkylcarbonylamino(C1-C6)alkyl, ((C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino, (C1-C6)alkoxycarbonyl)(C1-C6)alkylamino, (C1-C6)alkoxycarbonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbnony)((C1-C6)alkyl)amino(C1-C6)alkyl, carboxy, (C1-C6)alkoxycarbonyl, (C6-C10)aryl(C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C1-C6)alkylcarbonyl(C1-C6)alkyl, (C6-C10)arylcarbonyl, (C6-C10)arylcarbonyl(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylcarbonyl, (C6-C10)aryl(C1-C6)alkycarbonyl(C1-C6)alkyl, carboxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkoxycarbonyl(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkylcarbonyloxy(C1-C6)alkyl, aminocarbonyl, (C1-C6)alkylaminocarbonyl, ((C1-C6)alkyl)2aminocarbonyl, (C6-C10)arylaminocarbonyl, (C6-C10)aryl(C1-C6)alkylaminocarbonyl, aminocarbonyl(C1-C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkyl, (C6-C10)arylaminocarbonyl(C1-C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkyl, amidino, guanidino, ureido, (C1-C6)alkylureido, ((C1-C6)alkyl)2ureido, ureido(C1-C6)alkyl, (C1-C6)alkylureido(C1-C6)alkyl, ((C1-C6)alkyl)2ureido(C1-C6)alkyl, (C2-C9)heterocycloalkyl, (C2-C9)heteroaryl, (C2-C9)heterocycloalkyl(C1-C6)alkyl and (C2-C9)heteroaryl(C1-C6)alkyl;
each R2 and R3 are independently selected from oxo, halo, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C6)alkyl, (C3-C8)cycloalkylamino(C1-C6)alkyl, (C3-C-8)cycloalkyl(C1-C6)alkylamino(C1-C6)alkyl, halo(C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl, (C6-C10)aryl(C2-C6)alkenyl, H—C(O)—, H—C(O)—(C1-C6)alkyl, hydroxy(C1-C6)alkyl, hydroxy(C2-C6)alkenyl, hydroxy(C2-C6)alkynyl, hydroxy(C6-C10)aryl(C1-C6)alkyl, hydroxy(C3-C8)cycloalkyl(C1-C6)alkyl, thio(C1-C6)alkyl, cyano(C1-C6)alkyl, halo(C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C1-C6)alkoxy(C6-C10)aryl(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, (C6-C10)aryloxy(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkylthio(C1-C6)alkyl, (C1-C6)alkylsulfinyl(C1-C6)alkyl, (C1-C6)alkylsulfonyl(C1-C6)alkyl, hydroxy(C1-C6)alkylthio(C1-C6)alkyl, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkyl, (C6-C10)arylamino(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkylcarbonylamino(C1-C6)alkyl, azido(C1-C6)alkyl, aminocarbonylamino(C1-C6)alkyl, (C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonyl(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkyl, hydroxy(C1-C6)alkylamino(C1-C6)alkyl, (C6-C10)aryloxy(C1-C6)alkylcarbonyloxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkylcarbonyloxy(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkoxy(C1-C6)alkylcarbonyloxy(C1-C6)alkyl, (C1-C6)alkylcarbonyl, (C1-C6)alkylcarbonyl(C1-C6)alkyl, carboxy, (C1-C6)alkoxycarbonyl, (C6-C10)aryl(C1-C6)alkoxycarbonyl, (C6-C10)aryl(C1-C6)alkylcarbonyl, aminocarbonyl, (C1-C6)alkylaminocarbonyl, ((C1-C6)alkyl)2aminocarbonyl, (C6-C10)arylaminocarbonyl, (C6-C10)aryl(C1-C6)alkylaminocarbonyl, carboxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkoxycarbonyl(C1-C6)alkyl, aminocarbonyl(C1-C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkyl, (C6-C10)arylaminocarbonyl(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylaminocarbonyl(C1-C6)alkyl, (C6-C10)arylsulfonyl, (C2-C9)heterocycloalkyl, (C2-C9)heteroaryl, (C2-C9)heterocycloalkyl(C1-C6)alkyl, (C2-C9)heteroaryl(C1-C6)alkyl or R14R15N(C1-C6)alkyl wherein R14 and R15 are each independently (C1-C6)alkyl or (C1-C6)alkylcarbonyl;
R4 is (R5)f(R6)g(C6-C10)aryl, (R5)f(R6)g(C3-C10)cycloalkyl, (R5)f(R7)h(C2-C9)heteroaryl, or (R5)f(R7)h(C2-C9)heterocycloalkyl,
wherein f is 1, 2, 3 or 4;
g and h are each independently 0, 1, 2 or 3;
R5 is one to three groups independently selected from (C2-C9)heterocycloalkylcarbonyl, (C2-C9)heteroarylcarbonyl, (C2-C9)heteroaryl(C1-C6)alkylaminocarbonyl, (C2-C9)heterocycloalkyl(C1-C6)alkylaminocarbonyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylaminocarbonyl, ureido(C1-C6)alkylaminocarbonyl, (C1-C6)alkylureido(C1-C6)alkylaminocarbonyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylaminocarbonyl, halo(C1-C6)alkylaminocarbonyl, aminosulfonyl(C1-C6)alkylaminocarbonyl, (C1-C6)alkylaminosulfonyl(C1-C6)alkylaminocarbonyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylcarbonylamino, cyanoguanidino(C1-C6)alkylcarbonylamino, (C1-C6)alkylcyanoguanidino(C1-C6)alkylcarbonylamino, ((C1-C6)alkyl)2cyanoguanidino(C1-C6)alkylcarbonylamino, aminocarbonyl(C1-C6)alkylcarbonylamino, (C2-C9)heteroaryl(C1-C6)alkylcarbonylamino, (C2-C9)heterocycloalkyl(C1-C6)alkylcarbonylamino, aminosulfonyl(C1-C6)alkylcarbonylamino, hydroxy(C1-C6)alkylureido, amino(C1-C6)alkylureido, (C1-C6)alkylamino(C1-C6)alkylureido, ((C1-C6)alkyl)2amino(C1-C6)alkylureido, (C2-C9)heterocycloalkyl(C1-C6)alkylureido, (C2-C9)heteroaryl(C1-C6)alkylureido, aminosulfonyl(C1-C6)alkylureido, aminocarbonyl(C1-C6)alkylureido, (C1-C6)alkylaminocarbonyl(C1-C6)alkylureido, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkylureido, acetylamino(C1-C6)alkylureido, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylureido, halo(C1-C6)alkylsulfonylamino, amino(C1-C6)alkylsulfonylamino, (C1-C6)alkylamino(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2amino(C1-C6)alkylsulfonylamino, acetylamino(C1-C6)alkylsulfonylamino, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylsulfonylamino, ureido(C1-C6)alkylsulfonylamino, (C1-C6)alkylureido(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2ureido(C1-C6)alkylsulfonylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkylsulfonylamino, cyanoguanidino(C1-C6)alkylsulfonylamino, (C1-C6)alkylcyanoguanidino(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2cyanoguanidino(C1-C6)alkylsulfonylamino, aminocarbonyl(C1-C6)alkylsulfonylamino, (C1-C6)alkoxycarbonylamino(C1-C6)alkylsulfonylamino, aminosulfonylamino, (C1-C6)alkylaminosulfonylamino, ((C1-C6)alkyl)2aminosulfonylamino, aminocarbonyl(C1-C6)alkylamino(C1-C6)alkylsulfonylamino, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylsulfonylamino, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylsulfonylamino, cyanoguanidino, (C1-C6)alkylcyanoguanidino, ((C1-C6)alkyl)2cyanoguanidino, (C2-C9)heterocycloalkylcyanoguanidino, (C2-C9)heteroarylcyanoguanidino, (C2-C9)heterocycloalkyl(C1-C6)alkylcyanoguanidino, (C2-C9)heteroaryl(C1-C6)alkylcyanoguanidino, amino(C1-C6)alkylcyanoguanidino, (C1-C6)alkylamino(C1-C6)alkylcyanoguanidino, ((C1-C6)alkyl)2amino(C1-C6)alkylcyanoguanidino, aminocarbonyl(C1-C6)alkylcyanoguanidino, (C1-C6)alkylaminocarbonyl(C1-C6)alkylcyanoguanidino, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkylcyanoguanidino, aminocarbonyl(C1-C6)alkylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkylamino, (C1-C6)alkoxycarbonylamino(C1-C6)alkylamino, aminosulfonyl(C1-C6)alkylamino, (C2-C9)heteroaryl(C1-C6)alkylamino, acetylamino(C1-C6)alkylamino, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylamino, (C1-C6)alkoxycarbonyl(C1-C6)alkylamino(C1-C6)alkyl, cyano(C1-C6)alkylaminoalkyl, aminocarbonyl(C1-C6)alkylamino(C1-C6)alkyl, acetylamino(C1-C6)alkylamino(C1-C6)alkyl, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkylamino(C1-C6)alkyl, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylamino(C1-C6)alkyl, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylamino(C1-C6)alkyl, cyanoguanidino(C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkylcyanoguanidino(C1-C6)alkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2cyanoguanidino(C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylamino(C1-C6)alkyl, ureido(C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkylureido(C1-C6)alkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylamino(C1-C6)alkyl, aminocarbonyloxy(C1-C6)alkylamino(C1-C6)alkyl, aminocarbonyl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, aminosulfonyl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkyl, (C2-C9)heterocycloalkylcarbonylamino(C1-C6)alkylcarbonylamino(C1-C6)alkyl, cyanoguanidino(C1-C6)alkylcarbonylamino(C1-C6)alkyl cyano(C1-C6)alkylcarbonylamino(C1-C6)alkyl, amino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl hydroxy(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, aminocarbonyl(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl (C1-C6)alkylcarbonylamino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl (C2-C9)heterocycloalkyl(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C2-C9)heteroaryl(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, ureido(C1-C6)alkylureido(C1-C6)alkyl, (C1-C6)alkylureido(C1-C6)alkylureido(C1-C6)alkyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylureido(C1-C6)alkyl, cyanoguanidino(C1-C6)alkylureido(C1-C6)alkyl halo(C1-C6)alkylsulfonylamino(C1-C6)alkyl, amino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, acetylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylsulfonylamino(C1-C6)alkyl ureido(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkylureido(C1-C6)alkylsulfonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylsulfonylamino(C1-C6)alkyl (C1-C6)alkylsulfonylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl cyanoguanidino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkyl(cyanoguanidino)(C1-C6)alkylsulfonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2(cyanoguanidino)(C1-C6)alkylsulfonylamino(C1-C6)alkyl, aminocarbonyl(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, aminosulfonylamino(C1-C6)alkyl, (C1-C6)alkylaminosulfonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2aminosulfonylamino(C1-C6)alkyl, cyanoguanidino(C1-C6)alkyl, (C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, ((C1-C6)alkyl)2(cyanoguanidino)(C1-C6)alkyl, (C2-C9)heterocycloalkyl(cyanoguanidino)(C1-C6)alkyl, (C2-C9)heterocycloalkyl(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, (C2-C9)heterocycloalkyl(cyanoguanidino)amino, (C2-C9)heteroaryl(cyanoguanidino)(C1-C6)alkyl, (C2-C9)heteroaryl(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, amino(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, aminocarbonyl(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, aminosulfonyl, (C1-C6)alkylaminosulfonyl, ((C1-C6)alkyl)2aminosulfonyl, (C2-C9)heterocycloalkylsulfonyl, amino(C1-C6)alkylaminosulfonyl, (C1-C6)alkylamino(C1-C6)alkylaminosulfonyl, ((C1-C6)alkyl)2amino(C1-C6)alkylaminosulfonyl, (C2-C9)heteroarylaminosulfonyl, hydroxy(C1-C6)alkylaminosulfonyl, (C1-C6)alkoxy(C1-C6)alkylaminosulfonyl, ureido(C1-C6)alkylaminosulfonyl, (C1-C6)alkylureido(C1-C6)alkylaminosulfonyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylaminosulfonyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylaminosulfonyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkylaminosulfonyl, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylaminosulfonyl, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylaminosulfonyl, aminocarbonyl(C1-C6)alkylaminosulfonyl, cyanoguanidino(C1-C6)alkylaminosulfonyl, (C2-C9)heteroaryl(C1-C6)alkylaminosulfonyl, (C2-C9)heterocycloalkylaminosulfonyl, R6 is one to three groups independently selected from hydrogen, hydroxy, hydroxysulfonyl, halo, (C1-C6)alkyl, mercapto, mercapto(C1-C6)alkyl, (C1-C6)alkylthio, (C1-C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, (C6-C10)arylsulfonyl, (C1-C6)alkylthio(C1-C6)alkyl, (C1-C6)alkylsulfinyl(C1-C6)alkyl, (C1-C6)alkylsulfonyl(C1-C6)alkyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkoxy, (C6-C10)aryloxy, halo(C1-C6)alkyl, trifluoro(C1-C6)alkyl, formyl, formyl(C1-C6)alkyl, nitro, nitroso, cyano, (C6-C10)aryl(C1-C6)alkoxy, halo(C1-C6)alkoxy, trifluoro(C1-C6)alkoxy, amino(C1-C6)alkoxy, (C3-C10)cycloalkyl, (C3-C10)cycloalkyl(C1-C6)alkyl, hydroxy(C3-C10)cycloalkyl(C1-C6)alkyl, (C3-C10)cycloalkylamino, (C3-C10)cycloalkylamino(C1-C6)alkyl, cyano(C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl, (C6-C10)aryl(C2-C6)alkenyl, hydroxy(C1-C6)alkyl, (hydroxy) (C6-C10)aryl(C1-C6)alkyl, ((C1-C6)alkylamino)(C6-C10)aryl(C1-C6)alkyl, hydroxy(C1-C6)alkylthio(C1-C6)alkyl, hydroxy(C2-C6)alkenyl, hydroxy(C2-C6)alkenyl, hydroxy(C2-C6)alkynyl, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxy(C6-C10)aryl(C1-C6)alkyl, aryloxy(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkoxy(C1-C6)alkyl, amino, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, (C6-C10)arylamino, (C6-C10)aryl(C1-C6)alkylamino, amino(C1-C6)alkylamino, (C2-C9)heterocycloalkylamino, (C2-C9)heteroarylamino, (C3-C10)cycloalkyl(C1-C6)alkyl)amino, (C1-C6)alkylcarbonylamino, (C1-C6)alkoxycarbonylamino, (C2-C6)alkenylcarbonylamino, (C3-C10)cycloalkylcarbonylamino, (C6-C10)arylcarbonylamino, (C2-C9)heterocycloalkylcarbonylamino, halo(C1-C6)alkylcarbonylamino, (C1-C6)alkoxy(C1-C6)alkylcarbonylamino, (C1-C6)alkoxycarbonyl(C1-C6)alkylcarbonylamino, ((C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino, ((C1-C6)alkoxycarbonyl)((C1-C6)alkyl)amino, (C1-C6)alkylsulfonylamino, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkyl, hydroxy(C1-C6)alkylamino(C1-C6)alkyl, (C6-C10)arylamino(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C6-C10)arylcarbonylamino(C1-C6)alkyl, ((C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino(C1-C6)alkyl, C3-C10)cycloalkyl(C1-C6)alkyl)amino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonyl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, ((C1-C6)alkoxycarbonyl)((C1-C6)alkyl)amino(C1-C6)alkyl, (C1-C6)alkylsulfonylamino(C1-C6)alkyl, ((C1-C6)alkylsulfonyl)((C1-C6)alkyl)amino(C1-C6)alkyl, (C6-C10)arylsulfonylamino(C1-C6)alkyl, ((C6-C10)arylsulfonyl)((C1-C6)alkyl)amino(C1-C6)alkyl, (C2-C9)heterocycloalkylamino(C1-C6)alkyl, (C2-C9)heteroarylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C6-C10)aryl(C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C6-C10)arylcarbonyl, (C6-C10)aryl(C1-C6)alkylcarbonyl, hydroxy(C1-C6)alkoxycarbonyl, (C1-C6)alkoxycarbonyl(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkoxycarbonyl(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkylcarbonyloxy(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonyloxy(C1-C6)alkyl, (C1-C6)alkylcarbonyl(C1-C6)alkyl, (C6-C10)arylcarbonyl(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylcarbonyl(C1-C6)alkyl, aminocarbonyl, (C1-C6)alkylaminocarbonyl, ((C1-C6)alkyl)2aminocarbonyl, (C6-C10)arylaminocarbonyl, (C6-C10)aryl(C1-C6)alkylaminocarbonyl, (aminocarbonyl(C1-C6)alkylaminocarbonyl, ((C1-C6)alkylaminocarbonyl(C1-C6)alkylaminocarbonyl, ((C1-C6)alkoxycarbonyl(C1-C6)alkylaminocarbonyl, (amino(C1-C6)alkyl)aminocarbonyl, (hydroxy(C1-C6)alkylaminocarbonyl, aminocarbonyl(C1-C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkyl, (C6-C10)arylaminocarbonyl(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylaminocarbonyl(C1-C6)alkyl, amidino, hydroxyamidino, guanidino, ureido, (C1-C6)alkylureido, (C6-C10)arylureido, ((C6-C10)aryl)2ureido, (C6-C10)aryl(C1-C6)alkylureido, halo(C1-C6)alkylureido, ((C1-C6)alkyl)((C6-C10)aryl)ureido, ((C1-C6)alkyl)2ureido, halo(C1-C6)alkylcarbonylureido, ureido(C1-C6)alkyl, (C1-C6)alkylureido(C1-C6)alkyl, ((C1-C6)alkyl)2ureido(C1-C6)alkyl, (C6-C10)arylureido(C1-C6)alkyl, (C6-C10)aryl)2ureido(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylureido(C1-C6)alkyl, halo(C1-C6)alkylureido(C1-C6)alkyl, (halo(C1-C6)alkyl)((C1-C6)alkyl)ureido(C1-C6)alkyl, ((C1-C6)alkoxycarbonyl(C1-C6)alkyl)ureido(C1-C6)alkyl, glycinamido, (C1-C6)alkylglycinamido, aminocarbonylglycinamido, (C1-C6)alkoxy(C1-C6)alkylcarbonylglycinamido, (aminocarbonyl)((C1-C6)alkyl)glycinamido, ((C1-C6)alkoxycarbonyl(C1-C6)alkylcarbonyl)((C1-C6)alkyl)glycinamido, ((C1-C6)alkoxycarbonylamino(C1-C6)alkylcarbonyl)glycinamido, (C6-C10)arylcarbonylglycinamido, ((C6-C10)arylcarbonyl)((C1-C6)alkyl)glycinamido, ((C6-C10)aryl(C1-C6)alkylaminocarbonyl)glycinamido, (C6-C10)aryl(C1-C6)alkylaminocarbonyl)((C1-C6)alkyl)glycinamido, (C6-C10)arylaminocarbonylglycinamido, ((C6-C10)arylaminocarbonyl)((C1-C6)alkyl)glycinamido, glycinamido(C1-C6)alkyl, alaninamido, (C1-C6)alkylalaninamido, alaninamido(C1-C6)alkyl, (C2-C9)heteroaryl, (C2-C9)heterocycloalkyl, (C2-C9)heteroaryl(C1-C6)alkyl and (C2-C9)heterocycloalkyl(C1-C6)alkyl;
R7 is one to three groups independently selected from hydrogen, hydroxy, halo, (C1-C6)alkyl, (C1-Cr)alkylsulfonyl, (C6-C10)arylsulfonyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkoxy, halo(C1-C6)alkyl, fomyl, nitro, cyano, halo(C1-C6)alkoxy, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl, amino, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, (C6-C10)arylamino, (C6-C10)aryl(C1-C6)alkylamino, (C1-C6)alkylcarbonylamino, (C1-C6)alkoxycarbonylamino, (C2-C6)alkenylcarbonylamino, cycloalkylcarbonylamino, (C6-C10)arylcarbonylamino, halo(C1-C6)alkylcarbonylamino, (C1-C6)alkoxy(C1-C6)alkylcarbonylamino, (C1-C6)alkoxycarbonyl(C1-C6)alkylcarbonylamino, ((C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino, ((C1-C6)alkoxycarbonyl)((C1-C6)alkyl)amino, (C1-C6)alkylsulfonylamino, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkyl, (C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C6-C10)arylcarbonylamino(C1-C6)alkyl, ((C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C6-C10)aryl(C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C6-C10)arylcarbonyl, (C6-C10)aryl(C1-C6)alkylcarbonyl, aminocarbonyl, (C1-C6)alkylaminocarbonyl, ((C1-C6)alkyl)2aminocarbonyl, (C6-C10)arylaminocarbonyl, aminocarbonyl(C1-C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkyl, (C6-C10)arylaminocarbonyl(C1-C6)alkyl, guanidino, ureido, (C1-C6)alkylureido, ureido(C1-C6)alkyl, (C1-C6)alkylureido(C1-C6)alkyl, and glycinamido;
R9 and R10 are each independently selected from the group consisting of hydrogen, (C1-C6)alkyl, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl, (C1-C6)alkylcarbonyl, (C1-C6)alkylcarbonyl(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylcarbonyl, (C6-C10)aryl(C1-C6)alkylcarbonyl(C1-C6)alkyl, aminocarbonyl, (C1-C6)alkylaminocarbonyl, ((C1-C6)alkyl)2aminocarbonyl and (C1-C6)alkoxycarbonyl; and
R11 and R12 are each independently selected from the group consisting of hydrogen, (C1-C6)alkyl, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl, hydroxy, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, amino, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, (C1-C6)alkylcarbonylamino, (C3-C8)cycloalkylcarbonylamino, (C3-C8)cycloalkyl(C1-C6)alkylcarbonylamino, (C1-C6)alkoxycarbonylamino, (C1-C6)alkylsulfonylamino, (C6-C10)arylcarbonylamino, (C1-C6)alkoxycarbonyl(C1-C6)alkylcarbonylamino, (C6-C10)aryl(C1-C6)alkylcarbonylamino, ((C6-C10)aryl(C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino, (C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C3-C8)cycloalkylcarbonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkyl, (C2-C9)heterocycloalkylcarbonylamino(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C2-C9)heteroarylcarbonylamino(C1-C6)alkyl, (C6-C10)arylsulfonylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkyl, aminocarbonylamino, (C1-C6)alkylaminocarbonylamino, halo(C1-C6)alkylaminocarbonylamino, ((C1-C6)alkyl)2aminocarbonylamino, aminocarbonylamino(C1-C6)alkyl, (C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonylamino(C1-C6)alkyl, halo(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, amino(C1-C6)alkyl, (C1-C6ralkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkyl, carboxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl(C1-C6)alkyl, aminocarbonyl(C1-C6)alkyl and (C1-C6)alkylaminocarbonyl(C1-C6)alkyl.
2. A compound according to claim 1, wherein R1 is hydrogen, halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C1-C6)alkyl, hydroxy or (C1-C6)alkylcarbonyloxy.
3. A compound according to claim 1, wherein R2 and R3 are each independently selected from (C1-C6)alkyl, (C3-C8)cycloalkyl, amino(C1-C6)alkyl, amino(C3-C8)cycloalkyl, (C1-C6)alkylamino(C1-C6)alkyl, (C1-C6)alkylamino(C3-C8)cycloalkyl, hydroxy(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkyl, ureido(C1-C6)alkyl, (C1-C6)alkyureido(C1-C6)alkyl, (C2-C9)heteroaryl(C1-C6)alkyl or (C2-C9)heterocycloalkyl(C1-C6)alkyl.
4. A compound according to claim 1, wherein c is 1; X is C(O) of CH2; d is 2; Y is ethylene; and e is 0.
5. A compound according to claim 1, wherein c is 1; X is C(O) or CH2; d is for 2; Y is CH2 or ethylene; e is 1; and Z is oxygen or NR9 wherein R9 is hydrogen or (C1-C6)alkyl.
6. A compound according to claim 1, wherein c is 1; X is C(O) or CH2; d is 1; Y is CHR8 wherein R8 is NR9R10; R9 and R10 are each independently hydrogen, (C1-C6)alkyl or (C1-C6)alkylcarbonyl; e is 1; and Z is selected from the group consisting of oxygen, CR11R12 wherein R11 and R12 are hydrogen, and NR9 wherein R9 is hydrogen or (C1-C6)alkyl.
7. A compound according to claim 1, wherein R4 is (R5)f(R6)g(C6-C10)aryl or (R5)f(R7)h(C2-C9)heteroaryl wherein f, g and h are independently 1 or 2.
8. A compound according to claim 1, wherein R5 is selected from the group consisting of (C2-C9)heterocycloalkylcarbonyl, (C2-C9)heteroarylcarbonyl, (C2-C9)heteroaryl(C1-C6)alkylaminocarbonyl, (C2-C9)heterocycloalkyl(C1-C6)alkylaminocarbonyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylaminocarbonyl, ureido(C1-C6)alkylaminocarbonyl, (C1-C6)alkylureido(C1-C6)alkylaminocarbonyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylaminocarbonyl, aminosulfonyl(C1-C6)alkylaminocarbonyl, (C1-C6)alkylaminosulfonyl(C1-C6)alkylaminocarbonyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylcarbonylamino, cyanoguanidino(C1-C6)alkylcarbonylamino, (C1-C6)alkylcyanoguanidino(C1-C6)alkylcarbonylamino, ((C1-C6)alkyl)2cyanoguanidino(C1-C6)alkylcarbonylamino, aminocarbonyl(C1-C6)alkylcarbonylamino, (C2-C9)heteroaryl(C1-C6)alkylcarbonylamino, (C2-C9)heterocycloalkyl(C1-C6)alkylcarbonylamino, aminosulfonyl(C1-C6)alkylcarbonylamino, amino(C1-C6)alkylureido, (C1-C6)alkylamino(C1-C6)alkylureido, ((C1-C6)alkyl)2amino(C1-C6)alkylureido, (C2-C9)heterocycloalkyl(C1-C6)alkylureido, (C2-C9)heteroaryl(C1-C6)alkylureido, aminosulfonyl(C1-C6)alkylureido, aminocarbonyl(C1-C6)alkylureido, (C1-C6)alkylaminocarbonyl(C1-C6)alkylureido, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkylureido, acetylamino(C1-C6)alkylureido, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylureido, amino(C1-C6)alkylsulfonylamino, (C1-C6)alkylamino(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2amino(C1-C6)alkylsulfonylamino, acetylamino(C1-C6)alkylsulfonylamino, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylsulfonylamino ureido(C1-C6)alkylsulfonylamino, (C1-C6)alkylureido(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2ureido(C1-C6)alkylsulfonylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkylsulfonylamino, cyanoguanidino(C1-C6)alkylsulfonylamino, (C1-C6)alkylcyanoguanidino(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2cyanoguanidino(C1-C6)alkylsulfonylamino, aminocarbonyl(C1-C6)alkylsulfonylamino, (C1-C6)alkoxycarbonylamino(C1-C6)alkylsulfonylamino aminosulfonylamino, (C1-C6)alkylaminosulfonylamino, ((C1-C6)alkyl)2aminosulfonylamino, aminocarbonyl(C1-C6)alkylamino(C1-C6)alkylsulfonylamino, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylsulfonylamino (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylsulfonylamino, amino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl (C1-C6)alkylamino(C1-C6)alkylaminocarbonyl amino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, aminocarbonyl(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl (C1-C6) alkylcarbonylamino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl (C1-C6)alkoxycarbonyl amino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C2-C9)heterocycloalkyloxycarbonyl amino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl (C2-C9)heteroaryoxycarbonylamino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C2-C9)heterocycloalkyl(C1-C6)alkylaminocarbony lamino(C1-C6)alkyl, (C2-C9)heteroaryl(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, ureido(C1-C6)alkylureido(C1-C6)alkyl, (C1-C6)alkylureido(C1-C6)alkylureido(C1-C6)alkyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylureido(C1-C6)alkyl, cyanoguanidino(C1-C6)alkylureido(C1-C6)alkyl, amino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkylsulfonylamino(C1-C6)alkyl acetylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, ureido(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkylureido(C1-C6)alkylsulfonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, cyanoguanidino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkyl(cyanoguanidino)(C1-C6)alkylsulfonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2(cyanoguanidino)(C1-C6)alkylsulfonylamino(C1-C6)alkyl, aminocarbonyl(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, aminosulfonylamino(C1-C6)alkyl, (C1-C6)alkylaminosulfonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2aminosulfonylamino(C1-C6)alkyl, (C2-C9)heterocycloalkylsulfonyl, amino(C1-C6)alkylaminosulfonyl, (C1-C6)alkylamino(C1-C6)alkylaminosulfonyl, ((C1-C6)alkyl)2amino(C1-C6)alkylaminosulfonyl, (C2-C9)heteroarylaminosulfonyl, ureido(C1-C6)alkylaminosulfonyl, (C1-C6)alkylureido(C1-C6)alkylaminosulfonyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylaminosulfonyl, (C1-C6)alkylsulfonylamino(C1-C6)alkylaminosulfonyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkylaminosulfonyl, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylaminosulfonyl, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylaminosulfonyl, aminocarbonyl(C1-C6)alkylaminosulfonyl, cyanoguanidino(C1-C6)alkylaminosulfonyl, (C2-C9)heteroaryl(C1-C6)alkylaminosulfonyl, (C2-C9)heterocycloalkylaminosulfonyl halo(C1-C6)alkylaminocarbonyl, hydroxy(C1-C6)alkylureido, halo(C1-C6)alkylsulfonylamino, (C1-C6)alkoxycarbonyl(C1-C6)alkylamino(C1-C6)alkyl, hydroxy(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, halo(C1-C6)alkylsulfonylamino(C1-C6)alkyl, aminosulfonyl, (C1-C6)alkylaminosulfonyl, ((C1-C6)alkyl)2aminosulfonyl, hydroxy(C1-C6)alkylaminosulfonyl, and (C1-C6)alkoxy(C1-C6)alkylaminosulfonyl.
9. A compound according to claim 1, wherein R6 and R7 are each independently halo, halo(C1-C6)alkyl, (C1-C6)alkyl, (C1-C6)alkoxy, trifluoromethyl, trifluoromethoxy, hydroxy, aminocarbonyl, cyano, ureido, (C1-C6)alkylsulfonylamino, (C1-C6)alkoxycarbonylamino or glycinamino.
10. A pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases, rheumatoid arthritis, type I diabetes (recent onset), lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis, acute and chronic inflammatory conditions osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, glomerulonephritis, and chronic obstructive pulmonary disease (COPD) allergic conditions, asthma and atopic dermatitis, inflammation associated with infection, viral inflammation, influenza, hepatitis and Guillian-Barre, chronic bronchitis, chronic or acute tissue, cell, and solid organ transplant rejection, xeno-transplantation, atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases, sarcoidosis, leprosy and tuberculosis, and sequelae associated with cancers, multiple myelomax; limiting the production of cytokines and/or TNF at inflammatory sites, as a consequence of decreasing cell infiltration; for treating diseases and/or congestive heart failure, linked to TNF and IL-1 and for treating pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1, HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex), for treating sequelae associated with infection where such infection induces production of detrimental inflammatory cytokines and/or TNF, fungal meningitis, joint tissue damage, hyperplasia, pannus formation and bone resorption, psoriatic arthritis, hepatic failure, bacterial meningitis, Kawasaki syndrome, myocardial infarction, acute liver failure, lyme disease, septic shock, cancer, trauma, and malaria, in a mammal, comprising an amount of a compound according to claim 1, or a pharmaceutically acceptable salt or pro-drug thereof, that is effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.
11. A pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by inhibiting chemokine binding to the receptor CCR1 in a mammal, comprising an amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.
12. A method for treating or preventing a disorder or condition selected from autoimmune diseases, rheumatoid arthritis, type I diabetes (recent onset), lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis, acute and chronic inflammatory conditions osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, glomerulonephritis, and chronic obstructive pulmonary disease (COPD) allergic conditions, asthma and atopic dermatitis, inflammation associated with infection, viral inflammation, influenza, hepatitis and Guillian-Barre, chronic bronchitis, chronic or acute tissue, cell, and solid organ transplant rejection, xeno-transplantation, atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases, sarcoidosis, leprosy and tuberculosis, and sequelae associated with cancers, multiple myelomax; limiting the production of cytokines and/or TNF at inflammatory sites, as a consequence of decreasing cell infiltration; for treating diseases and/or congestive heart failure, linked to TNF and IL-1 and for treating pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1, HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex), for treating sequelae associated with infection where such infection induces production of detrimental inflammatory cytokines and/or TNF, fungal meningitis, joint tissue damage, hyperplasia, pannus formation and bone resorption, psoriatic arthritis, hepatic failure, bacterial meningitis, Kawasaki syndrome, myocardial infarction, acute liver failure, lyme disease, septic shock, cancer, trauma, and malaria, in a mammal, comprising administering to a mammal in need of such treatment or prevention an amount of a compound according to claim 1, or a pharmaceutically acceptable salt or pro-drug thereof, that is effective in treating or preventing such disorder or condition.
13. A method for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, comprising administering to a mammal in need of such treatment or prevention an amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.
US10/660,052 2000-03-31 2003-09-10 Novel piperazine derivatives Abandoned US20040058932A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/660,052 US20040058932A1 (en) 2000-03-31 2003-09-10 Novel piperazine derivatives

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19378900P 2000-03-31 2000-03-31
US09/821,322 US6649611B2 (en) 2000-03-31 2001-03-29 Piperazine derivatives
US10/660,052 US20040058932A1 (en) 2000-03-31 2003-09-10 Novel piperazine derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/821,322 Division US6649611B2 (en) 2000-03-31 2001-03-29 Piperazine derivatives

Publications (1)

Publication Number Publication Date
US20040058932A1 true US20040058932A1 (en) 2004-03-25

Family

ID=22715010

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/821,322 Expired - Fee Related US6649611B2 (en) 2000-03-31 2001-03-29 Piperazine derivatives
US10/660,052 Abandoned US20040058932A1 (en) 2000-03-31 2003-09-10 Novel piperazine derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/821,322 Expired - Fee Related US6649611B2 (en) 2000-03-31 2001-03-29 Piperazine derivatives

Country Status (34)

Country Link
US (2) US6649611B2 (en)
EP (1) EP1268455A2 (en)
JP (1) JP2003528867A (en)
KR (1) KR20020084273A (en)
CN (1) CN1450999A (en)
AP (1) AP2002002637A0 (en)
AR (1) AR033813A1 (en)
AU (1) AU2001239469A1 (en)
BG (1) BG107091A (en)
BR (1) BR0109703A (en)
CA (1) CA2404626A1 (en)
CZ (1) CZ20023154A3 (en)
DZ (1) DZ3306A1 (en)
EA (1) EA006079B1 (en)
EE (1) EE200200567A (en)
HR (1) HRP20020785A2 (en)
HU (1) HUP0300567A3 (en)
IL (1) IL151923A0 (en)
IS (1) IS6546A (en)
MA (1) MA26887A1 (en)
MX (1) MXPA02009645A (en)
NO (1) NO20024649D0 (en)
NZ (1) NZ521290A (en)
OA (1) OA12239A (en)
PA (1) PA8514401A1 (en)
PE (1) PE20011309A1 (en)
PL (1) PL358618A1 (en)
SK (1) SK13652002A3 (en)
SV (1) SV2002000356A (en)
TN (1) TNSN01047A1 (en)
UA (1) UA73553C2 (en)
WO (1) WO2001072728A2 (en)
YU (1) YU69902A (en)
ZA (1) ZA200207827B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293499A1 (en) * 2006-05-18 2007-12-20 Mannkind Corporation Intracellular Kinase Inhibitors

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002254124A1 (en) 2001-02-27 2002-09-12 Mitokor Aryl-n-cyanoguanidines and methods related thereto
WO2002102787A2 (en) 2001-06-20 2002-12-27 Pfizer Products Inc. Novel sulfonic acid derivatives
US6812230B2 (en) * 2001-08-07 2004-11-02 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists for the treatment of progressive renal fibrosis
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
EP1425029A4 (en) * 2001-08-10 2006-06-07 Palatin Technologies Inc Peptidomimetics of biologically active metallopeptides
MXPA04002423A (en) * 2001-10-22 2004-05-31 Pfizer Prod Inc Piperazine derivatives with ccr1 receptor antagonist activity.
MXPA04006709A (en) 2002-01-11 2004-10-04 Sankyo Co Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these.
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
DK1531822T3 (en) * 2002-06-12 2009-12-07 Chemocentryx Inc 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists in the treatment of inflammation and immune disorders
US7589199B2 (en) * 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
US20040087571A1 (en) * 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
US20040092529A1 (en) * 2002-10-30 2004-05-13 Pfizer Inc Methods of using piperazine derivatives
WO2004055031A1 (en) * 2002-12-13 2004-07-01 Pfizer Products Inc. Phosphorus-containing piperazine derivatives as ccr1 antagonists
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
SI21507A (en) 2003-05-16 2004-12-31 LEK farmacevtska dru�ba d.d. Procedure of preparation of compounds with ace inhibition effect
MXPA06001762A (en) * 2003-08-14 2006-05-12 Pfizer Piperazine derivatives for the treatment of hiv infections.
FR2864080B1 (en) 2003-12-23 2006-02-03 Sanofi Synthelabo 1-PIPERAZINE-AND-1-HOMOPIPERAZINE-CARBOXYLATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
CN1938029A (en) * 2004-02-06 2007-03-28 舍林股份公司 Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma
WO2005079788A1 (en) 2004-02-24 2005-09-01 Sankyo Company, Limited Amino alcohol compound
SE0400441D0 (en) 2004-02-25 2004-02-25 Active Biotech Ab Novel Benzofurans and Indols
FR2866888B1 (en) * 2004-02-26 2006-05-05 Sanofi Synthelabo ALKYLPIPERAZINE- AND ALKYLHOMOPIPERAZINE-CARBOXYLATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
WO2005084667A1 (en) * 2004-03-03 2005-09-15 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7829589B2 (en) * 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
US20060293370A1 (en) * 2005-06-10 2006-12-28 Saunders Jeffrey O Sulfonamide compounds and uses thereof
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
US20080102505A1 (en) * 2006-09-18 2008-05-01 Petrie Thomas R Jr Method of treating viral infections with ultraviolet light
ES2523739T3 (en) * 2010-01-05 2014-12-01 Actelion Pharmaceuticals Ltd. Piperazines as anti-malaria agents
US9439884B2 (en) * 2011-05-26 2016-09-13 Beth Israel Deaconess Medical Center, Inc. Methods for the treatment of immune disorders
US9730941B2 (en) 2012-06-07 2017-08-15 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of Pin1
US10351914B2 (en) 2014-07-17 2019-07-16 Beth Israel Deaconess Medical Center, Inc. Biomarkers for Pin1-associated disorders
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
US11166912B2 (en) 2016-03-03 2021-11-09 Ctt Pharma Inc. Orally administrable composition
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2020053654A1 (en) 2018-09-12 2020-03-19 Novartis Ag Antiviral pyridopyrazinedione compounds
AU2020353055B2 (en) 2019-09-26 2024-03-07 Gilead Sciences, Inc. Antiviral pyrazolopyridinone compounds
CN113754566B (en) * 2021-10-14 2023-03-21 山东新华制药股份有限公司 OAB-14 synthesis process

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3119742A (en) * 1962-12-19 1964-01-28 Smith Kline French Lab Method of preparing sustained release pharmaceutical pellets and product thereof
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4060596A (en) * 1972-09-30 1977-11-29 Sony Corporation Method of making goethite powder
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US5304558A (en) * 1990-07-10 1994-04-19 Kirin Brewery Co., Ltd. Diphenylmethyl piperazine derivatives
US5691340A (en) * 1994-09-15 1997-11-25 Adir Et Compagnie Benzopyran derivatives
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3119742A (en) * 1962-12-19 1964-01-28 Smith Kline French Lab Method of preparing sustained release pharmaceutical pellets and product thereof
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4060596A (en) * 1972-09-30 1977-11-29 Sony Corporation Method of making goethite powder
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US5304558A (en) * 1990-07-10 1994-04-19 Kirin Brewery Co., Ltd. Diphenylmethyl piperazine derivatives
US5691340A (en) * 1994-09-15 1997-11-25 Adir Et Compagnie Benzopyran derivatives
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293499A1 (en) * 2006-05-18 2007-12-20 Mannkind Corporation Intracellular Kinase Inhibitors
US8604031B2 (en) 2006-05-18 2013-12-10 Mannkind Corporation Intracellular kinase inhibitors

Also Published As

Publication number Publication date
PA8514401A1 (en) 2002-02-21
WO2001072728A2 (en) 2001-10-04
WO2001072728B1 (en) 2003-01-09
EP1268455A2 (en) 2003-01-02
AU2001239469A1 (en) 2001-10-08
MA26887A1 (en) 2004-12-20
EA200200873A1 (en) 2003-04-24
EE200200567A (en) 2004-06-15
AR033813A1 (en) 2004-01-07
CN1450999A (en) 2003-10-22
CA2404626A1 (en) 2001-10-04
EA006079B1 (en) 2005-08-25
PE20011309A1 (en) 2001-12-29
WO2001072728A9 (en) 2002-10-10
NO20024649L (en) 2002-09-27
JP2003528867A (en) 2003-09-30
BR0109703A (en) 2003-02-04
HRP20020785A2 (en) 2004-12-31
IS6546A (en) 2002-09-10
SV2002000356A (en) 2002-06-07
SK13652002A3 (en) 2004-01-08
NO20024649D0 (en) 2002-09-27
PL358618A1 (en) 2004-08-09
UA73553C2 (en) 2005-08-15
BG107091A (en) 2003-04-30
YU69902A (en) 2005-07-19
WO2001072728A3 (en) 2002-07-18
OA12239A (en) 2003-12-08
HUP0300567A2 (en) 2003-09-29
TNSN01047A1 (en) 2005-11-10
US20020107255A1 (en) 2002-08-08
NZ521290A (en) 2004-10-29
KR20020084273A (en) 2002-11-04
ZA200207827B (en) 2003-09-30
US6649611B2 (en) 2003-11-18
MXPA02009645A (en) 2003-03-10
AP2002002637A0 (en) 2002-09-30
CZ20023154A3 (en) 2003-11-12
HUP0300567A3 (en) 2003-11-28
IL151923A0 (en) 2003-04-10
DZ3306A1 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
US6649611B2 (en) Piperazine derivatives
US20050250790A1 (en) Novel sulfonic acid derivatives
US20020119961A1 (en) Bridged piperazine derivatives
WO2004009550A1 (en) Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1
KR20050028036A (en) Bicyclic piperidine derivatives as antagonists of the ccr1 chemokine receptor
US20040116441A1 (en) Methods of using sulfonic acid derivatives
AU2004274183B2 (en) Amidines and derivatives thereof and pharmaceutical compositions containing them
AU2002253477A1 (en) Novel sulfonic acid derivatives

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION